US20160067351A1 - Specific sites for modifying antibodies to make immunoconjugates - Google Patents

Specific sites for modifying antibodies to make immunoconjugates Download PDF

Info

Publication number
US20160067351A1
US20160067351A1 US14/764,026 US201414764026A US2016067351A1 US 20160067351 A1 US20160067351 A1 US 20160067351A1 US 201414764026 A US201414764026 A US 201414764026A US 2016067351 A1 US2016067351 A1 US 2016067351A1
Authority
US
United States
Prior art keywords
antibody
light chain
positions
heavy chain
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/764,026
Other languages
English (en)
Inventor
Bernhard Hubert GEIERSTANGER
Weijia Ou
Tetsuo Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to US14/764,026 priority Critical patent/US20160067351A1/en
Assigned to NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. reassignment NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: IRM LLC
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Publication of US20160067351A1 publication Critical patent/US20160067351A1/en
Assigned to NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. reassignment NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OU, WEIJIA, GEIERSTANGER, Bernhard Hubert, UNO, TETSUO
Assigned to IRM LLC reassignment IRM LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF)
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A61K47/48646—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/48384—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the invention provides specific sites for attaching moieties to antibodies for making modified antibodies, such as for use in preparation of antibody-drug conjugates (ADCs).
  • ADCs antibody-drug conjugates
  • the selective conjugation sites are located on constant regions of the antibody and thus are useful with various antibodies.
  • Heterogeneity of a pharmaceutical active ingredient is typically undesirable because it compounds the unpredictability of administering a drug to a heterogeneous population of subjects: it is far preferable to administer a homogeneous product, and far more difficult to fully characterize and predict behavior of a heterogeneous one.
  • Site-specific conjugation of a cytotoxic drug to an antibody through, for example, engineered cysteine residues results in homogenous immunoconjugates that exhibit improved therapeutic index (Junutula et al., (2008) Nat Biotechnol. 26(8):925-932)).
  • Antibodies have been engineered to add certain residues like cysteine in specific positions where these residues can be used for conjugation (Lyons et al., (1990) Protein Eng., 3:703-708), but the value of specific substitutions can vary with certain antibodies, as engineered cysteine might interfere with folding of the antibody and oxidation of the proper intra-molecular disulfide bonds (Voynov et al., (2010) Bioconjug. Chem. 21(2):385-392).
  • cysteines in antibodies expressed in mammalian cells are modified through disulfide bonds with glutathione (GSH) and/or cysteine during their biosynthesis (Chen et al. (2009) mAbs 1:6, 563-571)
  • the modified cysteine(s) in the antibody drug conjugate product as initially expressed is unreactive to thiol reactive reagents.
  • Activation of the engineered cysteine(s) requires reduction of the GSH and/or cysteine adduct (which typically results in reduction of all inter-chain disulfide bonds of the antibody), followed by reoxidation and reformation of the native, inter-chain disulfide bonds prior to conjugation (Junutula et al., (2008) Nat. Biotechnol.
  • site-specifically conjugated immunoconjugates can exhibit improved therapeutic index, thus there remains a need to identify specific privileged sites for cysteine substitution in antibodies that enables conjugation of payloads onto antibodies to form efficiently, and that provide conjugates having high stability.
  • the instant invention provides such privileged cysteine substitution sites that give improved antibodies for conjugation purposes and immunoconjugates comprising such improved antibodies.
  • the invention provides specific sites in the constant region of an antibody or antibody fragment at which cysteine (“Cys”) replacement of the native amino acid on a parental antibody or antibody fragment can be performed in order to provide a Cys residue for attachment of a chemical moiety (e.g., payload/drug moiety) to form an immunoconjugate with good efficiency and stability.
  • Cys cysteine
  • the invention further provides engineered antibodies or antibody fragments having one or more Cys residues in one or more of these specific sites, as well as immunoconjugates made from such engineered antibodies or antibody fragments.
  • the specific privileged sites for Cys replacement of native amino acids in the constant region of a parental antibody or antibody fragment are selected to provide efficient conjugation while minimizing undesired effects.
  • the specific sites for modification are selected so that replacing the native amino acid of a parental antibody or antibody fragment with Cys in one or more of the selected locations provides antibodies or antibody fragments that are readily conjugated on the new cysteine.
  • the specific locations are selected to be sufficiently surface-accessible to allow the sulfhydryl of the cysteine residue to be reactive towards electrophiles in aqueous solutions.
  • the identification of suitable sites for Cys replacement of native amino acids of a parental antibody or antibody fragment involved analyzing surface exposure of the native amino acids based on crystal structure data. Because the sites described herein are sufficiently accessible and reactive, they can be used to form immunoconjugates via chemistry that is well known in the art for modifying naturally-occurring cysteine residues. Conjugation of the replacement Cys residues thus uses conventional methods.
  • Selected modification sites can show a low propensity for reversal of conjugation when thiol-maleimide moieties are used in the conjugation.
  • the thiol-maleimide conjugation reaction is often highly selective and extremely efficient, and may be used either to attach a payload to the thiol of a cysteine residue of a protein or as a linker elsewhere in the linkage between protein and payload.
  • a maleimide can be attached to a protein (e.g., an antibody or antibody fragment), and a payload having an attached thiol can be added to the maleimide to form a conjugate:
  • the protein e.g., an antibody or antibody fragment
  • the immunoconjugate stability information specifically relates to conjugation of the substituted cysteine by reaction with a maleimide group.
  • the thiol is from a cysteine on the protein (e.g., an antibody or antibody fragment), so the double circle represents the protein and the single circle represents a payload.
  • the identification of the advantageous sites for meeting this criterion involved inserting Cys in place of many of the native amino acids having suitable surface exposure, making immunoconjugates containing a thiol-maleimide linkage, and assessing stability of the immunoconjugate in order to eliminate sites where the stability of the conjugate was reduced by the local microenvironment around destabilizing sites. Because of this, the chemistry that can be used to attach linkers and payloads to the replacement Cys residues is not limited by the stability problems associated with the reversibility of thiol-maleimide conjugates that is discussed above. A number of methods can be used to form conjugates at cysteine, including maleimide conjugation.
  • Selected sites can be positioned so as to minimize undesired disulfide formation that may interfere with formation of a homogeneous conjugate.
  • the Cys residues are typically present as disulfides to a free Cys amino acid or to glutathione (Chen et al., (2009) mAbs 16, 353-571).
  • the antibody or antibody fragment needs to be reduced, breaking all of the disulfide bonds. The antibody or antibody fragment is then reoxidized under conditions that facilitate formation of the native disulfides that stabilize the antibody or antibody fragment.
  • cysteine residues that are too prominently exposed on the surface of the antibody or antibody fragment can form disulfides by reaction with Cys on another antibody or antibody fragment (“inter-antibody disulfides”), or by forming undesired intra-antibody disulfides. It has been found that cysteine residues placed in the specific sites described herein are suitably accessible to be available for efficient conjugation, but are sufficiently shielded or suitably positioned to reduce or eliminate formation of inter-antibody and intra-antibody disulfide bonds that would otherwise occur during the reduction/reoxidation procedures typically needed when expressing cys-modified antibodies. Similarly, after re-oxidation some sites were found to produce non-homogenous conjugation products that appear to be due to the location of the new Cys residue engineered into the protein, and the specific sites identified herein are ones where such heterogeneity is minimized.
  • Conjugating drug payloads at sites where they are sequestered from solvent interactions and attachment can increase the hydrophobicity of the antibody upon drug attachment is preferred as reducing hydrophobicity of a protein drug is generally considered beneficial because it might reduce aggregation and clearance from circulation. Selecting attachment sites that result in minimal changes in hydrophobicity might be particularly beneficial when 4, 6 or 8 drugs are attached per antibody, or when particularly hydrophobic payloads are used.
  • Cysteine substitution sites are located in the constant region of an antibody or antibody fragment, and are identified herein using standard numbering conventions. It is well known, however, that portions or fragments of antibodies can be used for many purposes instead of intact full-length antibodies, and also that antibodies can be modified in various ways that affect numbering of sites in the constant region even though they do not substantially affect the functioning of the constant region. For example, insertion of an S6 tag (a short peptide) into a loop region of an antibody has been shown to allow activity of the antibody to be retained, even though it would change the numbering of many sites in the antibody.
  • cysteine substitution sites described herein are identified by a standard numbering system based on intact antibody numbering
  • the invention includes the corresponding sites in antibody fragments or in antibodies containing other modifications, such as peptide tag insertion.
  • the corresponding sites in those fragments or modified antibodies are thus preferred sites for cysteine substitution in fragments or modified antibodies, and references to the cysteine substitution sites by number include corresponding sites in modified antibodies or antibody fragments that retain the function of the relevant portion of the full-length antibody.
  • a corresponding site in an antibody fragment or modified antibody can readily be identified by aligning a segment of the antibody fragment or modified antibody with the full-length antibody to identify the site in the antibody fragment or modified antibody that matches one of the preferred cysteine substitution sites of the invention.
  • Alignment may be based on a segment long enough to ensure that the segment matches the correct portion of the full-length antibody, such as a segment of at least 20 amino acid residues, or at least 50 residues, or at least 100 residues, or at least 150 residues. Alignment may also take into account other modifications that may have been engineered into the antibody fragment or modified antibody, thus differences in sequence due to engineered point mutations in the segment used for alignment, particularly for conservative substitutions, would be allowed.
  • an Fc domain can be excised from an antibody, and would contain amino acid residues that correspond to the cysteine substitution sites described herein, despite numbering differences: sites in the Fc domain corresponding to the cysteine substitution sites of the invention would also be expected to be advantageous sites for cysteine substation in the Fc domain, and are included in the scope of the invention.
  • the invention provides an immunoconjugate of Formula (I):
  • Ab represents an antibody or antibody fragment comprising at least one cysteine residue at one of the preferred cysteine substitution sites described herein;
  • LU is a linker unit as described herein;
  • X is a payload or drug moiety
  • n is an integer from 1 to 16.
  • LU is attached to a cysteine at one of the cysteine substitution sites described herein,
  • X is a drug moiety such as an anticancer drug, and
  • n is 2-8 when Ab is an antibody, or n can be 1-8 when Ab is an antibody fragment.
  • the invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of one or more amino acids with cysteine on its constant region chosen from positions 121, 124, 152, 171, 174, 258, 292, 333, 360, and 375 of a heavy chain of said antibody or antibody fragment, and wherein said positions are numbered according to the EU system.
  • the invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of one or more amino acids with cysteine on its constant region chosen from positions 107, 108, 142, 145, 159, 161, and 165 of a light chain of said antibody or antibody fragment, wherein said positions are numbered according to the EU system, and wherein said light chain is human kappa light chain.
  • the invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of one or more amino acids with cysteine on its constant region chosen from positions 143, 147, 159, 163, and 168 of a light chain of said antibody or antibody fragment, wherein said positions are numbered according to the Kabat system, and wherein said light chain is human lambda light chain.
  • the invention provides a modified antibody or antibody fragment thereof comprising a substitution of one or more amino acids with cysteine at the positions described herein.
  • the sites for cysteine substitution are in the constant regions of the antibody and are thus applicable to a variety of antibodies, and the sites are selected to provide stable and homogeneous conjugates.
  • the modified antibody or fragment can have two or more cysteine substitutions, and these substitutions can be used in combination with other antibody modification and conjugation methods as described herein.
  • the invention provides pharmaceutical compositions comprising the immunoconjugate disclosed above, and methods to use the immunoconjugates.
  • the invention provides a nucleic acid encoding the modified antibody or antibody fragment described herein having at least one cysteine substitution at a site described herein.
  • the invention further provides host cells comprising these nucleic acids and methods to use the nucleic acid or host cells to express and produce the antibodies or fragments described herein.
  • the invention provides a method to select an amino acid of an antibody that is suitable for replacement by cysteine to provide a good site for conjugation, comprising:
  • the method further comprises a step of determining the melting temperature for the conjugate of each advantaged cysteine substitution site, and eliminating from the set any sites where cysteine substitution and conjugation causes the melting temperature to differ by 5° C. or more from that of the native antibody.
  • the invention provides a method to produce an immunoconjugate, which comprises attaching a Linker Unit (LU) or a Linker Unit-Payload combination (-LU-X) to a cysteine residue in an antibody or antibody fragment, wherein the cysteine is located at a cysteine substitution site selected from 121, 124, 152, 171, 174, 258, 292, 333, 360, and 375 of a heavy chain of said antibody or antibody fragment, and positions 107, 108, 142, 145, 159, 161, and 165 of a light chain of said antibody or antibody fragment, wherein said positions are numbered according to the EU system.
  • LU Linker Unit
  • -LU-X Linker Unit-Payload combination
  • amino acid refers to canonical, synthetic, and unnatural amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the canonical amino acids.
  • Canonical amino acids are proteinogenous amino acids encoded by the genetic code and include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline serine, threonine, tryptophan, tyrosine, valine, as well as selenocysteine, pyrrolysine and its analog pyrroline-carboxy-lysine.
  • Amino acid analogs refer to compounds that have the same basic chemical structure as a canonical amino acid, i.e., an ⁇ -carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., citrulline, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
  • Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a canonical amino acid.
  • Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that function in a manner similar to a canonical amino acid.
  • the term “unnatural amino acid”, as used herein, is intended to represent amino acid structures that cannot be generated biosynthetically in any organism using unmodified or modified genes from any organism, whether the same or different.
  • such “unnatural amino acids” typically require a modified tRNA and a modified tRNA synthetase (RS) for incorporation into a protein. This tRNA/RS pair preferentially incorporates the unnatural amino acid over canonical amino acids.
  • Such orthogonal tRNA/RS pair is generated by a selection process as developed by Schultz et al.
  • unnatural amino acid does not include the natural occurring 22 nd proteinogenic amino acid pyrrolysine (Pyl) as well as its demethylated analog pyrroline-carboxy-lysine (Pcl), because incorporation of both residues into proteins is mediated by the unmodified, naturally occurring pyrrolysyl-tRNA/tRNA synthetase pair and because Pyl and Pcl are generated biosynthetically (see, e.g., Ou et al., (2011) Proc. Natl. Acad. Sci.
  • antibody refers to a polypeptide of the immunoglobulin family that is capable of binding a corresponding antigen non-covalently, reversibly, and in a specific manner.
  • a naturally occurring IgG antibody is a tetramer comprising at least two heavy (H) chains (also referred to as “antibody heavy chain”) and two light (L) chains (also referred to as “antibody light chain”) inter-connected by disulfide bonds.
  • H heavy
  • L light
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V H ) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as V L ) and a light chain constant region.
  • the light chain constant region is comprised of one domain, C L .
  • the V H and V L regions can be further subdivided into regions of hyper variability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each V H and V L is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq
  • antibody includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camelid antibodies, chimeric antibodies, and anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention).
  • the antibodies can be of any isotype/class (e.g., IgG, IgE, IgM, IgD, IgA and IgY), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).
  • variable domains of both the light (V L ) and heavy (V H ) chain portions determine antigen recognition and specificity.
  • the constant domains of the light chain (C L ) and the heavy chain (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like.
  • the numbering of the constant region domains increases as they become more distal from the antigen binding site or amino-terminus of the antibody.
  • the N-terminus is a variable region and at the C-terminus is a constant region; the CH3 and C L domains actually comprise the carboxy-terminal domains of the heavy and light chain, respectively.
  • antibody fragment refers to either an antigen binding fragment of an antibody or a non-antigen binding fragment (e.g., Fc) of an antibody.
  • antigen binding fragment refers to one or more portions of an antibody that retain the ability to specifically interact with (e.g., by binding, steric hindrance, stabilizing/destabilizing, spatial distribution) an epitope of an antigen.
  • binding fragments include, but are not limited to, single-chain Fvs (scFv), disulfide-linked Fvs (sdFv), Fab fragments, F(ab′) fragments, a monovalent fragment consisting of the V L , V H , C L and CH1 domains; a F(ab) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the V H and CH1 domains; a Fv fragment consisting of the V L and V H domains of a single arm of an antibody; a dAb fragment (Ward et al., Nature 341:544-546, 1989), which consists of a V H domain; and an isolated complementarity determining region (CDR), or other epitope-binding fragments of an antibody.
  • scFv single-chain Fvs
  • sdFv disulfide-linked Fvs
  • Fab fragments F(
  • the two domains of the Fv fragment, V L and V H are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain Fv (“scFv”); see, e.g., Bird et al., Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. 85:5879-5883, 1988).
  • single chain Fv single chain Fv
  • Such single chain antibodies are also intended to be encompassed within the term “antigen binding fragment.” These antigen binding fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.
  • Antigen binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005).
  • Antigen binding fragments can be grafted into scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monobodies).
  • Fn3 fibronectin type III
  • Antigen binding fragments can be incorporated into single chain molecules comprising a pair of tandem Fv segments (V H -CH1-V H -CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al., Protein Eng. 8:1057-1062, 1995; and U.S. Pat. No. 5,641,870).
  • monoclonal antibody or “monoclonal antibody composition” as used herein refers to polypeptides, including antibodies and antibody fragments that have substantially identical amino acid sequence or are derived from the same genetic source. This term also includes preparations of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • human antibody includes antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. Furthermore, if the antibody contains a constant region, the constant region also is derived from such human sequences, e.g., human germline sequences, or mutated versions of human germline sequences or antibody containing consensus framework sequences derived from human framework sequences analysis, for example, as described in Knappik et al., J. Mol. Biol. 296:57-86, 2000).
  • the human antibodies of the invention may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo, or a conservative substitution to promote stability or manufacturing).
  • humanized antibody refers to an antibody that retains the reactivity of a non-human antibody while being less immunogenic in humans. This can be achieved, for instance, by retaining the non-human CDR regions and replacing the remaining parts of the antibody with their human counterparts. See, e.g., Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984); Morrison and Oi, Adv. Immunol., 44:65-92 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988); Padlan, Molec. Immun., 28:489-498 (1991); Padlan, Molec. Immun., 31(3):169-217 (1994).
  • epitopes refers to an antibody or antigen binding fragment thereof that finds and interacts (e.g., binds) with its epitope, whether that epitope is linear or conformational.
  • epitope refers to a site on an antigen to which an antibody or antigen binding fragment of the invention specifically binds.
  • Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
  • An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation.
  • Methods of determining spatial conformation of epitopes include techniques in the art, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996)).
  • affinity refers to the strength of interaction between antibody and antigen at single antigenic sites. Within each antigenic site, the variable region of the antibody “arm” interacts through weak non-covalent forces with antigen at numerous sites; the more interactions, the stronger the affinity.
  • isolated antibody refers to an antibody that is substantially free of other antibodies having different antigenic specificities.
  • An isolated antibody that specifically binds to one antigen may, however, have cross-reactivity to other antigens.
  • an isolated antibody may be substantially free of other cellular material and/or chemicals.
  • conservatively modified variant refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide.
  • nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid.
  • each codon in a nucleic acid except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan
  • TGG which is ordinarily the only codon for tryptophan
  • “conservatively modified variants” include individual substitutions, deletions or additions to a polypeptide sequence which result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
  • the following eight groups contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
  • the term “conservative sequence modifications” are used to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence.
  • the term “optimized” as used herein refers to a nucleotide sequence has been altered to encode an amino acid sequence using codons that are preferred in the production cell or organism, generally a eukaryotic cell, for example, a yeast cell, a Pichia cell, a fungal cell, a Trichoderma cell, a Chinese Hamster Ovary cell (CHO) or a human cell.
  • the optimized nucleotide sequence is engineered to retain completely or as much as possible the amino acid sequence originally encoded by the starting nucleotide sequence, which is also known as the “parental” sequence.
  • percent identical in the context of two or more nucleic acids or polypeptide sequences, refers to two or more sequences or subsequences that are the same.
  • Two sequences are “substantially identical” if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.
  • the identity exists over a region that is at least about 30 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • a “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
  • Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482c (1970), by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol.
  • BLAST and BLAST 2.0 algorithms Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra).
  • initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them.
  • the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always ⁇ 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: The cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787, 1993).
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
  • the percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci. 4:11-17, 1988) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch, J. Mol. Biol.
  • nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below.
  • a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.
  • Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below.
  • Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.
  • nucleic acid is used herein interchangeably with the term “polynucleotide” and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form.
  • the term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides.
  • Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
  • nucleic acid sequence also implicitly encompasses silent variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.
  • degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., (1991) Nucleic Acid Res. 19:5081; Ohtsuka et al., (1985) J. Biol. Chem. 260:2605-2608; and Rossolini et al., (1994) Mol. Cell. Probes 8:91-98).
  • operably linked in the context of nucleic acids refers to a functional relationship between two or more polynucleotide (e.g., DNA) segments. Typically, it refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence.
  • a promoter or enhancer sequence is operably linked to a coding sequence if it stimulates or modulates the transcription of the coding sequence in an appropriate host cell or other expression system.
  • promoter transcriptional regulatory sequences that are operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, i.e., they are cis-acting.
  • some transcriptional regulatory sequences, such as enhancers need not be physically contiguous or located in close proximity to the coding sequences whose transcription they enhance.
  • polypeptide and protein are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to canonical amino acid polymers as well as to non-canonical amino acid polymers. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.
  • immunoconjugate or “antibody conjugate” as used herein refers to the linkage of an antibody or an antibody fragment thereof with another agent, such as a chemotherapeutic agent, a toxin, an immunotherapeutic agent, an imaging probe, a spectroscopic probe, and the like.
  • the linkage can be through one or multiple covalent bonds, or non-covalent interactions, and can include chelation.
  • linkers many of which are known in the art, can be employed in order to form the immunoconjugate.
  • the immunoconjugate can be provided in the form of a fusion protein that may be expressed from a polynucleotide encoding the immunoconjugate.
  • fusion protein refers to proteins created through the joining of two or more genes or gene fragments which originally coded for separate proteins (including peptides and polypeptides). Fusion proteins may be created by joining at the N- or C-terminus, or by insertions of genes or gene fragments into permissible regions of one of the partner proteins. Translation of the fusion gene results in a single protein with functional properties derived from each of the original proteins.
  • subject includes human and non-human animals.
  • Non-human animals include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, and reptiles. Except when noted, the terms “patient” or “subject” are used herein interchangeably.
  • cytotoxin refers to any agent that is detrimental to the growth and proliferation of cells and may act to reduce, inhibit, or destroy a cell or malignancy.
  • anti-cancer agent refers to any agent that can be used to treat a cell proliferative disorder such as cancer, including but not limited to, cytotoxic agents, chemotherapeutic agents, radiotherapy and radiotherapeutic agents, targeted anti-cancer agents, and immunotherapeutic agents.
  • drug moiety or “payload” are used interchangeably and refers to a chemical moiety that is conjugated to the antibody or antibody fragment of the invention, and can include any moiety that is useful to attach to an antibody or antibody fragment.
  • a drug moiety or payload can be an anti-cancer agent, an anti-inflammatory agent, an antifungal agent, an antibacterial agent, an anti-parasitic agent, an anti-viral agent, an anesthetic agent.
  • a drug moiety is selected from a V-ATPase inhibitor, a HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizers, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor, an inhibitor of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a kinase inhibitor, a CDK2 inhibitor, a CDK9 inhibitor, a proteasome inhibitor, a kinesin inhibitor, an HDAC inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator, a DNA minor groove binder and a DHFR inhibitor.
  • a MetAP methionine aminopeptidase
  • an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor an inhibitor of phosphoryl transfer reactions in mitochondria
  • Suitable examples include auristatins such as MMAE and MMAF; calicheamycins such as gamma-calicheamycin; and maytansinoids such as DM1 and DM4.
  • auristatins such as MMAE and MMAF
  • calicheamycins such as gamma-calicheamycin
  • maytansinoids such as DM1 and DM4.
  • a payload can be a biophysical probe, a fluorophore, a spin label, an infrared probe an affinity probe, a chelator, a spectroscopic probe, a radioactive probe, a lipid molecule, a polyethylene glycol, a polymer, a spin label, DNA, RNA, a protein, a peptide, a surface, an antibody, an antibody fragment, a nanoparticle, a quantum dot, a liposome, a PLGA particle, a saccharide or a polysaccharide, a reactive functional group, or a binding agent that can connect the conjugate to another moiety, surface, etc.
  • drug antibody ratio refers to the number or payload or drug moieties linked to an antibody of the immunoconjugate.
  • a drug antibody of ratio of 2 means that average of two drug moieties bound to an each antibody in a sample of immunoconjugates.
  • the DAR in a sample of immunoconjugates can be “homogenous”.
  • a “homogenous conjugation sample” is a sample with a narrow distribution of DAR.
  • a homogenous conjugation sample having a DAR of 2 can contain within that sample antibodies that are not conjugated, and some antibodies having more than two moieties conjugated at about a DAR of two.
  • “Most of the sample” means have at least over 70%, or at least over 80% or at least over 90% of the antibodies in the sample will be conjugated to two moieties.
  • a homogenous conjugation sample having a DAR of 4 can contain within that sample antibodies that have more or fewer than four moieties conjugated at about a DAR of four.
  • “Most of the sample” means have at least over 70%, or at least over 80% or at least over 90% of the antibodies in the sample will be conjugated to four moieties.
  • in a homogenous conjugation sample having a DAR of 6 can contain within that sample antibodies that are have more or fewer than six moieties conjugated at about a DAR of six.
  • “Most of the sample” means have at least over 70%, or at least over 80% or at least over 90% of the antibodies in the sample will be conjugated to six moieties.
  • a homogenous conjugation sample having a DAR of 8 can contain within that sample antibodies that has some antibodies having fewer or more than eight moieties conjugated at about a DAR of four. “Most of the sample” means have at least over 70%, or at least over 80% or at least over 90% of the antibodies in the sample will be conjugated to eight moieties.
  • An immunoconjugate having a “drug antibody ratio of about 2” refers to sample of immunoconjugates where in the drug antibody ratio can range from about 1.6-2.4 moieties/antibody, 1.8-2.3 moieties/antibody, or 1.9-2.1 moieties/antibody.
  • An immunoconjugate having a “drug antibody ratio of about 4” refers to sample of immunoconjugates where in the drug antibody ratio can range from about 3.6-4.4 moieties/antibody, 3.8-4.3 moieties/antibody, or 3.9-4.1 moieties/antibody.
  • An immunoconjugate having a “drug antibody ratio of about 6” refers to sample of immunoconjugates where in the drug antibody ratio can range from about 5.6-6.4 moieties/antibody, 5.8-6.3 moieties/antibody, or 5.9-6.1 moieties/antibody.
  • An immunoconjugate having a “drug antibody ratio of about 8” refers to sample of immunoconjugates where in the drug antibody ratio can range from about 7.6-84 moieties/antibody, 7.8-8.3 moieties/antibody, or 7.9-8.1 moieties/antibody.
  • Tumor refers to neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • anti-tumor activity means a reduction in the rate of tumor cell proliferation, viability, or metastatic activity.
  • a possible way of showing anti-tumor activity is to show a decline in growth rate of abnormal cells that arises during therapy or tumor size stability or reduction.
  • Such activity can be assessed using accepted in vitro or in vivo tumor models, including but not limited to xenograft models, allograft models, MMTV models, and other known models known in the art to investigate anti-tumor activity.
  • malignancy refers to a non-benign tumor or a cancer.
  • cancer includes a malignancy characterized by deregulated or uncontrolled cell growth.
  • Exemplary cancers include: carcinomas, sarcomas, leukemias, and lymphomas.
  • cancer includes primary malignant tumors (e.g., those whose cells have not migrated to sites in the subject's body other than the site of the original tumor) and secondary malignant tumors (e.g., those arising from metastasis, the migration of tumor cells to secondary sites that are different from the site of the original tumor).
  • primary malignant tumors e.g., those whose cells have not migrated to sites in the subject's body other than the site of the original tumor
  • secondary malignant tumors e.g., those arising from metastasis, the migration of tumor cells to secondary sites that are different from the site of the original tumor.
  • an optical isomer or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other.
  • a 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
  • the term is used to designate a racemic mixture where appropriate.
  • “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or ( ⁇ ) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
  • the present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
  • Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • salt refers to an acid addition or base addition salt of a compound of the invention.
  • Salts include in particular “pharmaceutical acceptable salts”.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlorotheophyllinate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydr
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 Cl, 125 I respectively.
  • the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labeled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • the term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • the term “a therapeutically effective amount” refers to the amount of a compound of the present invention that, when administered to a subject, is effective to at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease, or at least partially inhibit activity of a targeted enzyme or receptor.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • thiol-maleimide as used herein describes a group formed by reaction of a thiol with maleimide, having this general formula
  • Y and Z are groups to be connected via the thiol-maleimide linkage and can be linker units, and can be attached to antibodies or payloads.
  • Y is an engineered antibody according to the invention, and the sulfur atom shown in the formula is from a cysteine at one of the substitution sites described herein; while Z represents a linker unit connected to a payload.
  • Linker Unit refers to a covalent chemical connection between two moieties, such as an antibody and a payload.
  • Each LU can be comprised of one or more components described herein as L 1 , L 2 , L 3 , L 4 , L 5 and L 6 .
  • the linker unit can be selected to provide suitable spacing between the connected moieties, or to provide certain physicochemical properties, or to allow cleavage of the linker unit under certain conditions.
  • “Cleavable” as used herein refers to a linker or linker unit (LU) that connects two moieties by covalent connections, but breaks down to sever the covalent connection between the moieties under physiological conditions. Cleavage may be enzymatic or non-enzymatic, but generally releases a payload from an antibody without degrading the antibody.
  • Non-cleavable refers to a linker or linker unit (LU) that is not susceptible to breaking down under physiological conditions. While the linker may be modified physiologically, it keeps the payload connected to the antibody until the antibody is substantially degraded, i.e., the antibody degradation precedes cleavage of the linker in vivo.
  • Cyclooctyne refers to an 8-membered ring containing a carbon-carbon triple bond (acetylene).
  • the ring is optionally fused to one or two phenyl rings, which may be substituted with 1-4 C 1-4 alkyl, C 1-4 alkoxy, halo, hydroxyl, COOH, COOL 1 , —C(O)NH-L 1 , O-L 1 , or similar groups, and which may contain N, O or S as a ring member.
  • cyclooctyne can be a C 8 hydrocarbon ring, particularly an isolated ring that is saturated aside from the triple bond, and may be substituted with F or Hydroxy, and may be linked to a linker or LU via —O—, —C(O), C(O)NH, or C(O)O.
  • Cyclooctene refers to an 8-membered ring containing at least one double bond, especially a trans-double bond.
  • the ring is optionally fused to one or two phenyl rings, which may be substituted with 1-4 C 1-4 alkyl, C 1-4 alkoxy, halo, hydroxyl, COOH, COOL 1 , —C(O)NH-L 1 , O-L 1 , or similar groups, and which may contain N, O or S as a ring member.
  • cyclooctene can be an isolated C 8 hydrocarbon ring that is saturated aside from the trans double bond and is optionally substituted with F or Hydroxy, and may be linked to a linker or LU via —O—, —C(O), C(O)NH, or C(O)O.
  • FIG. 1 Surface accessibility plot of amino acid residues in human IgG1 heavy chain (A) and kappa light chain (B). Surface accessibility was calculated using Surface Racer 5.0 and is expressed as Angstrom square [ ⁇ 2 ].
  • FIG. 2 Location of selected 92 TAG mutations in the structure of a human IgG1 with a kappa light chain. Selected residues for TAG mutations are shown in black on only one of the two heavy chains and for one of the two kappa light chains (1HZH.pdb). Structures are shown using PyMOL, an open-source molecular modeling package (The PyMOL Molecular Graphics System, Version 1.5.0. Schrödinger. LLC).
  • FIG. 3 The amino acid sequence alignment of the heavy chain constant regions of trastuzumab and antibody 14090. Residues mutated to Cys in the trastuzumab antibody and in antibody 14090 are underlined. Amino acid residues in heavy chain are numbered by Eu numbering system (Edelman et al., 1969).
  • FIG. 4 Amino acid sequence alignment of constant regions of trastuzumab, human IgG1, IgG2, IgG3 and IgG4.
  • FIG. 5 The amino acid sequence alignment of the constant regions of human kappa and lambda light chains.
  • FIG. 6 Analysis of trastuzumab Cys antibodies by non-reducing SDS-PAGE.
  • FIG. 7 Size exclusion chromatography of the trastuzumab LC-S156C mutant antibody (dashed line) and wild-type trastuzumab (solid line).
  • FIG. 8 Analysis of wild-type trastuzumab (A) and the trastuzumab LC-E158C mutant antibody (B) by reverse phase high pressure liquid chromatography (RP-HPLC).
  • FIG. 9 MS analysis of trastuzumab LC-R108C mutant antibody after Protein A purification (intact MS).
  • FIG. 10 Structure of MC-MMAF.
  • FIG. 11 Analysis of conjugation mixtures of trastuzumab Cys antibodies with MC-MMAF by RP-HPLC.
  • RP-HPLC traces of the conjugation mixtures are shown as dashed lines.
  • RP-HPLC traces of unmodified antibodies are shown as solid lines.
  • FIG. 12 Analysis of conjugation mixtures of trastuzumab Cys antibodies with MC-MMAF by RP-HPLC.
  • RP-HPLC traces of the conjugation mixtures are shown as dashed lines.
  • RP-HPLC traces of unmodified antibodies are shown as solid lines.
  • FIG. 13 Analysis of trastuzumab Cys-MMAF ADCs by analytical size-exclusion chromatography (AnSEC).
  • Trastuzumab HC-K290C-MMAF ADC short dashed line
  • trastuzumab LC-R142C-MMAF ADC dashed line
  • trastuzumab LC-L154C-MMAF ADC dotted line
  • solid line unmodified wild-type trastuzumab
  • FIG. 14 Thermal melting curve of unmodified wild-type trastuzumab and trastuzumab HC-T335C-MMAF, trastuzumab HC-S337C-MMAF and trastuzumab HC-K360C-MMAF ADCs.
  • FIG. 15 Cell proliferation assays for trastuzumab LC-S159C-MMAF with A. HCC1954, B. MDA-MB231 clone 16 and C. MDA-MB231 clone 40 cells.
  • FIG. 16 IC 50 of trastuzumab Cys-MMAF ADCs in MDA-MB231 clone 16 cell proliferation assay.
  • FIG. 17 Cell proliferation assays for Antibody 14090 HC-S375C-MMAF ADC with A. CMK11-5 and B. Jurkat cells.
  • FIG. 18 Pharmacokinetics study of trastuzumab LC-Cys-MMAF ADCs displaying no significant drug lost.
  • FIG. 19 Pharmacokinetics study of trastuzumab HC-Cys-MMAF ADCs displaying no significant drug lost.
  • FIG. 20 Pharmacokinetics study of trastuzumab Cys-MMAF ADCs displaying significant drug lost.
  • FIG. 21 Pharmacokinetics study of two trastuzumab Cys-MMAF ADCs displaying fast clearance in vivo.
  • FIG. 22 In vivo efficacy studies of trastuzumab Cys-MMAF ADCs in MDA-MB231 clone 16 xenograft mouse model.
  • FIG. 23 Retention times of trastuzumab Pcl MMAF DAR 2 ADCs as measured by Hydrophobic Interaction Chromotography. ABA-MMAF is attached at a Pcl residue substituted for the indicated HC or LC residue. A) HC conjugated ADCs. B) LC conjugated ADCs. The retention time of unconjugated wild-type antibody is indicated (WT).
  • FIG. 24 Location of selected payload sites in the structure of a human IgG1 with a kappa light chain. Selected residues are shown in black on only one of the two heavy chains and for one of the two kappa light chains (1HZH.pdb). Three rotations of the structure are shown using PyMOL, an open-source molecular modeling package (The PyMOL Molecular Graphics System, Version 1.5.0. Schrödinger, LLC).
  • FIG. 25 Pharmacokinetics study of trastuzumab and antibody 14090 Cys-MMAF ADCs with DAR 4, 6 and 8 prepared with antibodies with 2, 3 or 4 Cys mutations.
  • DAR 4 trastuzumab ADCs HC-E258C-LC-S159C-MMAF (A), HC-S375C-LC-S159C-MMAF (B), HC-E258C-LC-E165C-MMAF (C), HC-S375C-LC-E165C-MMAF (D), HC-E152C-LC-R142C-MMAF (E), HC-P171C-LC-R142C-MMAF, and HC-E152C-LC-S159C-MMAF (G); DAR 4 antibody 14090 ADCs: HC-S375C-LC-A143C-MMAF (H), HC-K360C-LC-V159C-MMAF (I), and HC-S375C-LC-V159C-MMAF (J);
  • Antibody 14090 is mouse cross-reactive and therefore is cleared more rapidly that then the trastuzumab ADCs which do not bind to any mouse antigens.
  • the present invention provides methods of site-specific labeling of antibodies or antibody fragments by replacing one or more amino acids of a parental antibody or antibody fragment at specific positions with cysteine amino acids (“Cys”), such that the engineered antibodies or antibody fragments are capable of conjugation to various agents (e.g., cytotoxic agents).
  • Cys cysteine amino acids
  • the present invention also provides immunoconjugates that are produced by using the methods described herein.
  • cysteine When a cysteine is engineered into a parental antibody or antibody fragment, the modified antibody or antibody fragment is first recovered from the expression medium with cysteine or glutathione (GSH) attached at the engineered cysteine site(s) via a disulfide linkage (Chen et al., (2009) mAbs 16, 353-571). The attached cysteine or GSH is then removed in a reduction step, which also reduces all native inter-chain disulfide bonds of the parental antibody or antibody fragment. In a second step these disulfide bonds are re-oxidized before conjugation occurs.
  • GSH cysteine or glutathione
  • the present invention provides unique sets of sites on the antibody heavy chain constant region and antibody light chain constant region, respectively, where Cys substitution as described herein produces modified antibodies or antibody fragments that perform well in the re-oxidation process, and also produce stable and well behaved immunoconjugates.
  • the site-specific antibody labeling according to the present invention can be achieved with a variety of chemically accessible labeling reagents, such as anti-cancer agents, fluorophores, peptides, sugars, detergents, polyethylene glycols, immune potentiators, radio-imaging probes, prodrugs, and other molecules.
  • chemically accessible labeling reagents such as anti-cancer agents, fluorophores, peptides, sugars, detergents, polyethylene glycols, immune potentiators, radio-imaging probes, prodrugs, and other molecules.
  • the present invention provides methods of preparation of homogeneous immunoconjugates with a defined drug-to-antibody ratio for use in cancer therapy and other indications as well as imaging reagents.
  • the present invention also provides immunoconjugates prepared thereby, as well as pharmaceutical compositions comprising these immunoconjugates.
  • the methods of the instant invention can be used in combination with other conjugation methods known in the art.
  • the immunoconjugate comprises a group of the formula
  • the cysteine substitution site may be a position that corresponds to one of the sites identified by a position number, even though the position of the site in the sequence has been changed by a modification or truncation of the full-length antibody.
  • Corresponding sites can be readily identified by alignment of an antibody or fragment with a full-length antibody.
  • the antibodies (e.g., a parent antibody, optionally containing one or more non-canonical amino acids) of the present invention are numbered according to the EU numbering system as set forth in Edelman et al., (1969) Proc. Natl. Acad. USA 63:78-85, except that the lambda light chain is numbered according to the Kabat numbering system as set forth in Kabat et al., (1991) Fifth Edition. NIH Publication No. 91-3242.
  • Human IgG1 constant region is used as a representative throughout the application. However, the invention is not limited to human IgG1; corresponding amino acid positions can be readily deduced by sequence alignment. For example, FIG.
  • IgG1, IgG2, IgG3 and IgG4 heavy chain constant regions show sequence alignment of human IgG1, IgG2, IgG3 and IgG4 heavy chain constant regions, so that an identified Cys engineering site in the IgG1 constant region can be readily identified for IgG2, IgG3, and IgG4 as shown in FIG. 4 .
  • IgG1, IgG2, IgG3 and IgG4 are the same.
  • Table 1 lists the amino acid positions in the constant region of the heavy chain of an antibody that can be replaced by a cysteine.
  • Table 2 lists the amino acid positions in the constant region of the kappa light chain of an antibody that can be replaced by a cysteine.
  • Table 3 lists the amino acid positions in the constant region of the lambda light chain of an antibody that can be replaced by a cysteine.
  • findings of the invention are not limited to any specific antibodies or antibody fragments.
  • the present invention provides immunoconjugates comprising a modified antibody or an antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises a substitution of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acids on its heavy chain constant region chosen from positions identified in Table 1.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of one or more amino acids with cysteine on its constant region chosen from positions 121, 124, 152, 171, 174, 258, 292, 333, 334, 360, 375, and 392 of the heavy chain.
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of two amino acids with cysteine on its constant region chosen from positions 121 and 124, 121 and 152, 121 and 171, 121 and 174, 121 and 258, 121 and 292, 121 and 333, 121 and 334, 121 and 360, 121 and 375, 121 and 392, 124 and 152, 124 and 171, 124 and 174, 124 and 258, 124 and 292, 124 and 333, 124 and 334, 124 and 360, 124 and 375, 124 and 392, 152 and 171, 152 and 174, 152 and 258, 152 and 292, 152 and 333, 152 and 334, 152 and 360, 152 and 375, 152 and 392, 171 and 174, 171 and 258, 171 and 292, 171 and 333, 171 and 360, 171 and 375, 174 and 392,
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of three amino acids with cysteine on its constant region chosen from positions 121, 124 and 152; 121, 124 and 171; 121, 124 and 174; 121, 124 and 258; 121, 124 and 292; 121, 124 and 333; 121, 124 and 334; 121, 124 and 360; 121, 124 and 375; 121, 124 and 392; 121, 152 and 171; 121, 152 and 174; 121, 152 and 258; 121, 152 and 292; 121, 152 and 333; 121, 152 and 334; 121, 152 and 360; 121, 152 and 375; 121, 152 and 392; 121, 171 and 174; 121, 171 and 258; 121, 171 and 292; 121, 171 and 2
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of four amino acids with cysteine on its constant region chosen from positions 152, 333, 375 and 392; or 152, 334, 375 and 392 of the heavy chain.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises SEQ ID NO: 2, 3, 9, 11, 12, 13, 14, 16, 21, 25, 26, 28, 30, 31, 32, 33, 34, 36, 38, 39, 40, 43, 44, 45, 46, 47, 51, 53, 54, 56, 57, or 60.
  • the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises SEQ ID NO: 6, 7, 8, 15, 19, 20, 22, 23, 24, 27, 36, 37, 41, 49, 52, 55, 58, or 59.
  • the present invention provides immunoconjugates comprising a modified antibody or an antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises a substitution of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) on its light chain constant region chosen from positions identified in Table 2.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of one or more amino acids with cysteine on its constant region chosen from positions 107, 108, 142, 145, 159, 161, and 165 of the light chain, wherein said light chain is human kappa light chain.
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of two amino acids with cysteine on its constant region chosen from positions 107 and 108; 107 and 142; 107 and 145; 107 and 159; 107 and 161; 107 and 165; 108 and 142; 108 and 145; 108 and 159; 108 and 161; 108 and 165; 142 and 145; 142 and 159; 142 and 161; 142 and 165; 145 and 159; 145 and 161; 145 and 165; 159 and 161; 159 and 165; 161 and 165 of the light chain, wherein said light chain is human kappa light chain.
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of three amino acids with cysteine on its constant region chosen from positions 107, 108 and 142; 107, 108 and 145; 107, 108 and 159; 107, 108 and 161; 107, 108 and 165; 107, 142 and 145; 107, 142 and 159; 107, 142 and 161; 107, 142 and 165; 107, 145 and 159; 107, 145 and 161; 107, 145 and 165; 107, 159 and 161; 107, 159 and 165; 107, 161 and 165; 108, 142 and 145; 108, 142 and 159; 108, 142 and 161; 108, 142 and 165; 108, 145 and 159; 108, 142 and 161; 108, 142 and 165; 108, 145
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises SEQ ID NO: 63, 65, 68, 70, 72, 73, 74, 78, 79, 80, 81, 82, 83, 86, 87, or 88.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises SEQ ID NO: 64, 66, 67, 84, 85, or 89 63, 64, 65, 66, 67, 68, 70, 72, 73, 74, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, or 89.
  • the present invention provides immunoconjugates comprising a modified antibody or an antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises a substitution of one or more amino acids on its light chain constant region chosen from positions identified in Table 3.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of one or more amino acids with cysteine on its constant region chosen from positions 143, 147, 159, 163, and 168 of the light chain, wherein said light chain positions are numbered according to the Kabat system, and wherein said light chain is human lambda light chain.
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of two amino acids with cysteine on its constant region chosen from positions 143 and 147; 143 and 159; 143 and 163; 143 and 168; 147 and 159; 147 and 163; 147 and 168; 159 and 163; 159 and 168; or 163 and 168 of the light chain, wherein said light chain positions are numbered according to the Kabat system, and wherein said light chain is human lambda light chain.
  • an immunoconjugate of the invention comprises a modified antibody or antibody fragment thereof and a drug moiety, wherein said modified antibody or antibody fragment comprises a substitution of three amino acids with cysteine on its constant region chosen from positions 143, 147 and 159; 143, 147 and 163; 143, 147 and 168; 143, 159 and 163; 143, 159 and 168; 143, 163 and 168; 147, 159 and 163; 147, 159 and 168; 147, 163 and 168; or 159, 163 and 168 of the light chain, wherein said light chain positions are numbered according to the Kabat system, and wherein said light chain is human lambda light chain.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises SEQ ID NO: 92, 94, 96, 97 or 98.
  • the present invention provides an immunoconjugate comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment thereof comprises SEQ ID NO: 93 or 95.
  • the immunoconjugate can have an DAR of about 2 or about 4.
  • the present invention provides immunoconjugates comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment comprises a Cys substitution of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acids on its heavy chain constant region chosen from positions identified in Table 1, and a Cys substitution of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acids on its light chain constant region chosen from positions identified in Table 2 or Table 3.
  • the present invention provides immunoconjugates comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment comprises a Cys substitution of one or more amino acids in its heavy chain constant region chosen from positions 121, 124, 152, 171, 174, 258, 292, 333, 334, 360, 375 and 392; and a Cys substitution of one or more amino acids in its light chain constant region chosen from positions 107, 108, 142, 145, 159, 161, and 165, wherein said light chain is human kappa light chain.
  • a modified antibody or antibody fragment according to the present invention may comprise a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 107 of a human kappa light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 108 of a human kappa light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 142 of a human kappa light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 145 of a human kappa light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 159 of a human kappa light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 161 of a human kappa light chain; or a Cys substitution on position 121 of a heavy chain,
  • a modified antibody or antibody fragment according to the present invention comprises a Cys substitution on position 375 and on position 392 of a heavy chain, and a Cys substitution on position 165 of a human kappa light chain.
  • a modified antibody or antibody fragment according to the present invention may comprise a Cys substitution on position 334 and on position 375 of a heavy chain, and a Cys substitution on position 165 of a human kappa light chain.
  • a modified antibody or antibody fragment according to the present invention may comprise a Cys substitution on position 334 and on position 392 of a heavy chain, and a Cys substitution on position 165 of a human kappa light chain.
  • an immunoconjugates of those combinations can have a DAR of about 4 or about 6.
  • a modified antibody or antibody fragment according to the present invention may comprise a Cys substitution on position 334, on position 375 and on position 392 of a heavy chain, and a Cys substitution on position 165 of a human kappa light chain.
  • a modified antibody or antibody fragment according to the present invention may comprise a Cys substitution on position 333, on position 375 and on position 392 of a heavy chain, and a Cys substitution on position 165 of a human kappa light chain.
  • those combinations can have a DAR of about 4, 6, or 8.
  • the present invention provides immunoconjugates comprising a modified antibody or antibody fragment thereof, and a drug moiety, wherein said modified antibody or antibody fragment comprises a Cys substitution of one or more amino acids in its heavy chain constant region chosen from positions 121, 124, 152, 171, 174, 258, 292, 333, 334 360, 375 and 392; and a Cys substitution of one or more amino acids in its light chain constant region chosen from positions 143, 147, 159, 163, and 168, wherein said light chain is human lambda light chain.
  • a modified antibody or antibody fragment according to the present invention may comprise a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 143 of a human lambda light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 147 of a human lambda light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 159 of a human lambda light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 163 of a human lambda light chain; or a Cys substitution on position 121 of a heavy chain, and a Cys substitution on position 168 of a human lambda light chain; or a Cys substitution on position 124 of a heavy chain, and a Cys substitution on position 143 of a human lambda light chain; or a Cys substitution on position 124 of a heavy chain, and a Cys substitution on position
  • the amino acid substitution described herein is cysteine comprising a thiol group.
  • the thiol group is utilized for chemical conjugation, and is attached to a linker unit (LU) and/or drug moiety.
  • the immunoconjugates of the invention comprise a drug moiety selected from the group consisting of a V-ATPase inhibitor, a HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizers, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor, proteasome inhibitors, an inhibitors of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a kinase inhibitor, a CDK2 inhibitor, a CDK9 inhibitor, an kinesin inhibitor, an HDAC inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator, a DNA minor groove binder and a DHFR inhibitor.
  • a drug moiety selected from the group consisting of a V-ATPase inhibitor, a HSP90 inhibitor, an
  • the immunoconjugates of the invention comprise a drug moiety that is an anti-cancer agent.
  • the modified antibody or antibody fragments of the present invention can be any formats known in the art, such as a monoclonal, chimeric, humanized, fully human, bispecific, or multispecific antibody or antibody fragment thereof.
  • the modified antibody heavy chain and/or light chain may contain 1, 2, 3, 4, 5, 6, 7, 8, or more cysteine substitutions in its constant regions.
  • the modified antibodies or antibody fragments contain 2, 4, 6, 8, or more cysteine substitutions in its constant regions.
  • the modified antibody, antibody fragment or immunoconjugate thereof comprises 2 or 4 Cys substitutions.
  • the parental antibody (antibody without cysteine substitution) is an IgG, IgM, IgE, or IgA antibody. In a specific embodiment, the parental antibody is an IgG1 antibody. In another specific embodiment, the parental antibody is an IgG2, IgG3, or IgG4 antibody.
  • the present invention also provides modified antibodies or antibody fragments thereof comprising a substitution of one or more amino acids on its heavy chain constant region chosen from positions identified in Table 1.
  • the present invention provides modified antibodies or antibody fragments thereof comprising a substitution of one or more amino acids on its light chain constant region chosen from positions identified in Table 2 or Table 3.
  • the modified antibodies or antibody fragments provided herein are labeled using the methods of the invention in combination with other conjugation methods known in the art including, but not limited to, chemoselective conjugation through lysine, histidine, tyrosine, formyl-glycine, pyrrolysine, pyrroline-carboxy-lysine, unnatural amino acids, and protein tags for enzyme-mediated conjugation (e.g., S6 tags).
  • conjugation methods including, but not limited to, chemoselective conjugation through lysine, histidine, tyrosine, formyl-glycine, pyrrolysine, pyrroline-carboxy-lysine, unnatural amino acids, and protein tags for enzyme-mediated conjugation (e.g., S6 tags).
  • the conjugated antibody or antibody fragment thereof provided herein is produced by post-translational modification of at least one cysteine residue that was incorporated into the antibody or antibody fragment thereof as described above by site-specific labeling methods.
  • the conjugated antibody or antibody fragment can be prepared by methods known in the art for conjugation of a payload of interest to cysteine residues that occur naturally in proteins, and by methods described for conjugation to proteins engineered to contain an additional cysteine residue substituted for another amino acid of a natural protein sequence.
  • modified antibodies or antibody fragment thereof provided herein are conjugated using known methods wherein the incorporated cysteine (cys) is conjugated to a maleimide derivative as Scheme Ia below.
  • Modified antibodies of the invention that undergo this type of conjugation contain a thiol-maleimide linkage.
  • LU is a Linker Unit (LU)
  • X is a payload or drug moiety.
  • the Cys incorporated into the modified antibodies or antibody fragment is conjugated by reaction with an alpha-halo carbonyl compound such as a chloro-, bromo-, or iodo-acetamide as shown in Scheme Ib below. It is understood that other leaving groups besides halogen, such as tosylate, triflate and other alkyl or aryl sulfonates, can be used as the leaving group Y.
  • Scheme Ib depicts reaction of a Cys thiol with an alpha-halo acetamide
  • the method includes any alkylation of a sulfur of an incorporated Cys with a group of the formula Y—CHR—C( ⁇ O)—, where R is H or C 1-4 alkyl, Y is a leaving group (typically Cl, Br, or I, and optionally an alkylsulfonate or arylsulfonate); it is not limited to amides.
  • the Cys incorporated into the modified antibodies or antibody fragment can be conjugated by reaction with an external thiol under conditions that induce formation of a disulfide bond between the external thiol and the sulfur atom of the incorporated cysteine residue as shown in Scheme Ic below.
  • R can be H; however, compounds where one or both R groups represent an alkyl group, e.g., Methyl, have been found to increase the stability of the disulfide.
  • the modified antibodies of the invention typically contain 1-12, frequently 2-8, and preferably 2, 4 or 6-LU-X (Linker Unit-Payload) moieties.
  • an antibody light or heavy chain is modified to incorporate two new Cys residues at two of the specific sites identified herein for Cys substitutions (or alternatively one Cys is incorporated in the light chain and one in the heavy chain), so the tetrameric antibody ultimately contains four conjugation sites.
  • the antibody can be modified by replacement of 3 or 4 of its native amino acids with Cys at the specific sites identified herein, in light chain or heavy chain or a combination thereof, resulting in 6 or 8 conjugation sites in the tetrameric antibody.
  • X in these conjugates represents a payload, which can be any chemical moiety that is useful to attach to an antibody.
  • X is a drug moiety selected from a cytotoxin, an anti-cancer agent, an anti-inflammatory agent, an antifungal agent, an antibacterial agent, an anti-parasitic agent, an anti-viral agent, an immune potentiator, and an anesthetic agent or any other therapeutic, or biologically active moiety or drug moiety.
  • X is a label such as a biophysical probe, a fluorophore, an affinity probe, a spectroscopic probe, a radioactive probe, a spin label, or a quantum dot.
  • X is a chemical moiety that modifies the antibody's physicochemical properties such as a lipid molecule, a polyethylene glycol, a polymer, a polysaccharide, a liposome, or a chelator.
  • X is a functional or detectable biomolecule such as a nucleic acid, a ribonucleic acid, a protein, a peptide (e.g., an enzyme or receptor), a sugar or polysaccharide, an antibody, or an antibody fragment.
  • X is an anchoring moiety such as a nanoparticle, a PLGA particle, or a surface, or any binding moiety for specifically binding the conjugate to another moiety, such as a histidine tag, poly-G, biotin, avidin, streptavidin, and the like.
  • X is a reactive functional group that can be used to attach the antibody conjugate to another chemical moiety, such as a drug moiety, a label, another antibody, another chemical moiety, or a surface.
  • the Linker Unit can be any suitable chemical moiety that covalently attaches the thiol-reactive group (e.g., maleimide, alpha-halo carbonyl, vinyl carbonyl (e.g., acrylate or acrylamide), vinyl sulfone, vinylpyridine, or thiol) to a payload.
  • thiol-reactive group e.g., maleimide, alpha-halo carbonyl, vinyl carbonyl (e.g., acrylate or acrylamide), vinyl sulfone, vinylpyridine, or thiol
  • LU can be comprised of one, two, three, four, five, six, or more than six linkers referred to herein as L 1 , L 2 , L 3 , L 4 , L 5 and L 6 .
  • the LU comprises a linker selected from a non-enzymatically cleavable linker, a non-cleavable linker, an enzymatically cleavable linker, a photo-stable linker, a photo-cleavable linker or any combination thereof, and the LU optionally contains a self-immolative spacer.
  • LU is a group of the formula -L 1 -L 2 -L 3 -L 4 - or -L 1 -L-L 3 -L 4 -L 5 -L 6 -.
  • Linking groups L 1 , L 2 , L 3 , L 4 , L 5 and L 6 for use in LU include alkylene groups —(CH 2 ) n — (where n is 1-20, typically 1-10 or 1-6), ethylene glycol units (—CH 2 CH 2 O—) n (where n is 1-20, typically 1-10 or 1-6), amides —C( ⁇ O)—NH— or —NH—C( ⁇ O)—, esters —C( ⁇ O)—O— or —O—C( ⁇ O)—, rings having two available points of attachment such as divalent phenyl, C 3-8 cycloalkyl or C 4-8 heterocyclyl groups, amino acids —NH—CHR*—C ⁇ O— or —C( ⁇ O)
  • L 1 , L 2 , L 3 , L 4 , L 5 and L 6 can be selected from:
  • At least one of L 1 , L 2 , L 3 , L 4 , L 5 and L 6 is a stable, or non-cleavable, linker.
  • at least one of L 1 , L 2 , L 3 , L 4 , L 5 and L 6 is a cleavable linker, which may be chemically cleavable (hydrazones, disulfides) or enzymatically cleavable.
  • the enzymatically cleavable linker is one readily cleaved by a peptidase: The Val-Cit linker (valine-citrulline), a dipeptide of two known amino acids, is one such linker.
  • the enzymatically cleavable linker is one that is triggered by activity of a glucuronidase:
  • linker which also comprises a self-immolative spacer that falls apart spontaneously under physiological conditions once glucuronidase cleaves the glycosidic linkage.
  • the immunoconjugate of the invention comprises a modified cysteine residue of the formula IIA or IIB:
  • L 2 is a bond.
  • L 2 is NH or O.
  • L 3 is selected from (CH 2 ) 1-10 and (CH 2 CH 2 O) 1-6 .
  • L 4 , L 5 and L 6 are additional optional linkers selected from those described herein.
  • L 6 can be a carbonyl (C ⁇ O) or a linker that comprises a self-immolative spacer.
  • the Linker Unit is -L 1 -L 2 -L 3 -L 4 -, wherein:
  • the Linker Unit is -L 1 -L 2 -L 3 -L 4 -, wherein
  • At least one of L 1 , L 2 , L 3 , L 4 , L 5 and L 6 is a cleavable linker, and LU is considered cleavable.
  • at least one of L 1 , L 2 , L 3 , L 4 , L 5 and L 6 is a non-cleavable linker.
  • each linker of LU is non-cleavable, and LU is considered non-cleavable.
  • L 1 , L 2 , L 3 and L 4 are linkers selected from -A 1 -, -A 1 X 2 — and —X 2 —;
  • R 9 is independently selected from H and C 1-6 haloalkyl
  • the other linkers of LU are independently selected from a bond, -A 1 -, -A 1 X 2 —, —X 2 —, a non-enzymatically cleavable linker, a non-cleavable linker, an enzymatically cleavable linker, a photo-stable linker, a photo-cleavable linker and a linker that comprises a self-immolative spacer.
  • the Linker Unit is -L 1 -L 2 -L 3 -L 4 -, wherein
  • L 1 is C( ⁇ O)—CH 2 CH 2 —NH—C( ⁇ O)—CH 2 CH 2 —S—, so LU is —C( ⁇ O)—CH 2 CH 2 —NH—C( ⁇ O)—CH 2 CH 2 —S-L 2 -L 3 -L 4 -.
  • the Linker Unit is -L 1 -L 2 -L 3 -L 4 -, wherein
  • the Linker Unit is -L 1 -L 2 -L 3 -L 4 -, wherein
  • R 9 is independently selected from H and C 1-6 haloalkyl; each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9, and each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8 and 9.
  • L 1 is —(CH 2 ) 1-10 —C( ⁇ O)—, e.g., —(CH 2 ) 5 —C( ⁇ O)—; and L 2 , L 3 and L 4 each represent a bond.
  • LU comprises a val-cit linker of this formula, wherein X represents a payload, typically a drug moiety such as one having anticancer activity:
  • L 3 is preferably —(CH 2 ) 2-6 —C( ⁇ O)—.
  • the X group is a maytansinoid such as DM1 or DM4, or a dolastatin analog or derivative such as dolastatin 10 or 15 and auristatins MMAF or MMAE, or a calicheamicin such as N-acetyl- ⁇ -calicheamicin, or a label or dye such as rhodamine or tetramethylrhodamine.
  • a maytansinoid such as DM1 or DM4
  • a dolastatin analog or derivative such as dolastatin 10 or 15 and auristatins MMAF or MMAE
  • a calicheamicin such as N-acetyl- ⁇ -calicheamicin
  • a label or dye such as rhodamine or tetramethylrhodamine.
  • a “linker” is any chemical moiety that is capable of connecting an antibody or a fragment thereof to an X group (payload) to form an immunoconjugate.
  • Linkers can be susceptible to cleavage, such as, acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage, at conditions under which the compound or the antibody remains active.
  • linkers can be substantially resistant to cleavage.
  • a linker may or may not include a self-immolative spacer.
  • Non-limiting examples of the non-enzymatically cleavable linkers as used herein to conjugate an X 1 group to the modified antibodies or antibody fragment thereof provided herein include, acid-labile linkers, linkers containing a disulfide moiety, linkers containing a triazole moiety, linkers containing a hydrazone moiety, linkers containing a thioether moiety, linkers containing a diazo moiety, linkers containing an oxime moiety, linkers containing an amide moiety and linkers containing an acetamide moiety.
  • Non-limiting examples of the enzymatically cleavable linkers as used herein to conjugate an X group to the modified antibodies or antibody fragment thereof provided herein include, but are not limited to, linkers that are cleaved by a protease, linkers that are cleaved by an amidase, and linkers that are cleaved by -glucuronidase or another glycosidase.
  • such enzyme cleavable linkers are linkers which are cleaved by cathepsin, including cathepsin Z, cathepsin B, cathepsin H and cathepsin C.
  • the enzymatically cleavable linker is a dipeptide cleaved by cathepsin, including dipeptides cleaved by cathepsin Z, cathepsin B, cathepsin H or cathepsin C.
  • the enzymatically cleavable linker is a cathepsin B-cleavable peptide linker.
  • the enzymatically cleavable linker is a cathepsin B-cleavable dipeptide linker. In certain embodiments the enzymatically cleavable dipeptide linker is valine-citrulline or phenylalanine-lysine.
  • Other non-limiting examples of the enzymatically cleavable linkers as used herein conjugate an X group to the modified antibodies or antibody fragment thereof provided herein include, but are not limited to, linkers which are cleaved
  • “Self-immolative spacers” are bifunctional chemical moieties covalently linked at one terminus to a first chemical moiety and at the other terminus to a second chemical moiety, thereby forming a stable tripartate molecule.
  • a linker can comprise a self-immolative spacer bonded to a third chemical moiety that is cleavable from the spacer either chemically or enzymatically. Upon cleavage of a bond between the self-immolative spacer and the first chemical moiety or the third chemical moiety, self-immolative spacers undergo rapid and spontaneous intramolecular reactions and thereby separate from the second chemical moiety.
  • the first or third moiety is an enzyme cleavable group, and this cleavage results from an enzymatic reaction, while in other embodiments the first or third moiety is an acid labile group and this cleavage occurs due to a change in pH.
  • the second moiety is the “Payload” group as defined herein.
  • cleavage of the first or third moiety from the self-immolative spacer results from cleavage by a proteolytic enzyme, while in other embodiments it results from cleaved by a hydrolase. In certain embodiments, cleavage of the first or third moiety from the self-immolative spacer results from cleavage by a cathepsin enzyme or a glucuronidase.
  • the enzyme cleavable linker is a peptide linker and the self-immolative spacer is covalently linked at one of its ends to the peptide linker and covalently linked at its other end to a drug moiety.
  • This tripartite molecule is stable and pharmacologically inactive in the absence of an enzyme, but which is enzymatically cleavable by enzyme at a bond covalently linking the spacer moiety and the peptide moiety.
  • the peptide moiety is cleaved from the tripartate molecule which initiates the self-immolating character of the spacer moiety, resulting in spontaneous cleavage of the bond covalently linking the spacer moiety to the drug moiety, to thereby effect release of the drug in pharmacologically active form.
  • a linker comprises a self-immolative spacer that connects to the peptide, either directly or indirectly at one end, and to a payload at the other end; and the spacer is attached to a third moiety that can be cleaved from the spacer enzymatically, such as by a glucuronidase. Upon cleavage of the third moiety, the spacer degrades or rearranges in a way that causes the payload to be released.
  • linker with this type of self-immolative spacer is this glucuronidase-cleavable linker, where hydrolysis of the acetal catalyzed by glucuronidase releases a phenolic compound that spontaneously decomposes under physiological conditions:
  • Non-limiting examples of the self-immolative spacer optionally used in the conjugation of an X 1 group to the modified antibodies or antibody fragment thereof provided herein include, but are not limited to, moieties which include a benzyl carbonyl moiety, a benzyl ether moiety, a 4-aminobutyrate moiety, a hemithioaminal moiety or a N-acylhemithioaminal moiety.
  • self-immolative spacers include, but are not limited to, p-aminobenzyloxycarbonyl groups, aromatic compounds that are electronically similar to the p-aminobenzyloxycarbonyl group, such as 2-aminoimidazol-5-methanol derivatives and ortho or para-aminobenzylacetals.
  • self-immolative spacers used herein which undergo cyclization upon amide bond hydrolysis include substituted and unsubstituted 4-aminobutyric acid amides and 2-aminophenylpropionic acid amides.
  • the self-immolative spacer is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe-immolative spacer
  • n 1 or 2.
  • the self-immolative spacer is
  • n 1 or 2.
  • the self-immolative spacer is
  • n 1 or 2.
  • the self-immolative spacer is
  • n 1 or 2.
  • the self-immolative spacer is
  • n 1 or 2.
  • Schemes (2a-2c) illustrate the post-translational modification of the modified antibodies or antibody fragment thereof provided herein wherein the Linker Unit (LU) is -L 1 -L 2 -L 3 -L 4 -, and L1 in each case is the group that reacts with the new Cys.
  • the Linker Unit LU
  • L1 in each case is the group that reacts with the new Cys.
  • the starting material is the replacement Cys residue in an antibody or antibody fragment modified as described herein, where the dashed bonds indicate connection to adjoining residues of the antibody or antibody fragment; each R is H or C 1-4 alkyl, typically H or methyl; L 2 , L 3 and L 4 are components of the linking unit LU, such as those described above; X is the payload; and the group connecting L 2 to the sulfur of the substitute Cys of the invention is L 1 .
  • X is a reactive functional group that can be used to connect the conjugated antibody to another chemical moiety, by interacting with a suitable complementary functional group.
  • Table 4 depicts some examples of reactive functional groups that X can represent, along with a complementary functional group that can be used to connect a conjugate comprising X to another compound.
  • Methods for using X to connect to the corresponding complementary functional group are well known in the art. Connections using azide are typically done using ‘Click’ or copper-free click chemistry; reactions involving hydrazines, alkoxyamines or acyl hydrazines typically proceed through the formation of a Schiff base with one of the carbonyl functional groups.
  • Payload X a is a reactive functional group
  • X b on Formula II-a is the corresponding complementary functional group
  • Formula II-a itself represents a molecule to be connected to the conjugated antibody.
  • the third column in Table 5 depicts a product from reaction of X a with X b .
  • the modified antibody or antibody fragment thereof provided herein is conjugated with an “X group-to-antibody” (payload to antibody) ratio between about 1 and 16, such as 1-12, or 1, 2, 3, 4, 5, 6, 7, or 8, wherein the modified antibody or antibody fragment thereof contains 1, 2, 3, 4, 5, 6, 7, or 8 cysteine residues incorporated at the specific sites disclosed herein.
  • an “X group-to-antibody” ratio of 4 can be achieved by incorporating two Cys residues into the heavy chain of an antibody, which will contain 4 conjugation sites, two from each heavy chain Immunoconjugates of such antibodies will contain up to 4 payload groups, which may be alike or different and are preferably all alike.
  • an “X group-to-antibody” ratio of 4 can be achieved by incorporating one Cys residue into the heavy chain and a second Cys residue into the light chain of an antibody resulting in 4 conjugation sites, two in the two heavy chains and two in the two light chains.
  • a ratio 6, 8 or higher can be achieved by combinations of 3, 4 or more cysteine substitutions of the invention in heavy and light chain of the antibody. Substituting multiple cysteine groups into an antibody can lead to inappropriate disulfide formation and other problems.
  • the methods of the invention can alternatively be combined with methods that do not rely upon reactions at cysteine sulfur, such as acylations at lysine, or conjugation via S6 tags or Pcl methodology.
  • the payload to antibody ratio has an exact value for a specific conjugate molecule, it is understood that the value will often be an average value when used to describe a sample containing many molecules, due to some degree of inhomogeneity, typically in the conjugation step.
  • the average loading for a sample of an immunoconjugate is referred to herein as the drug to antibody ratio, or DAR.
  • the DAR is between about 1 and about 16, and typically is about 1, 2, 3, 4, 5, 6, 7, or 8.
  • at least 50% of a sample by weight is compound having the average ratio plus or minus 2, and preferably at least 50% of the sample is a conjugate that contains the average ratio plus or minus 1.
  • Preferred embodiments include immunoconjugates wherein the DAR is about 2 or about 8, e.g., about 2, about 4, about 6 or about 8.
  • a DAR of ‘about n’ means the measured value for DAR is within 10% of n (in Formula (I)).
  • the present invention provides site-specific labeled immunoconjugates.
  • the immunoconjugates of the invention may comprise modified antibodies or antibody fragments thereof that further comprise modifications to framework residues within V H and/or V L , e.g. to improve the properties of the antibody.
  • framework modifications are made to decrease the immunogenicity of the antibody.
  • one approach is to “back-mutate” one or more framework residues to the corresponding germline sequence.
  • an antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequences from which the antibody is derived.
  • somatic mutations can be “back-mutated” to the germline sequence by, for example, site-directed mutagenesis.
  • Such “back-mutated” antibodies are also intended to be encompassed by the invention.
  • Another type of framework modification involves mutating one or more residues within the framework region, or even within one or more CDR regions, to remove T-cell epitopes to thereby reduce the potential immunogenicity of the antibody. This approach is also referred to as “deimmunization” and is described in further detail in U.S. Patent Publication No. 20030153043 by Carr et al.
  • antibodies of the invention may be engineered to include modifications within the Fc region, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and/or antigen-dependent cellular cytotoxicity.
  • modifications within the Fc region typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and/or antigen-dependent cellular cytotoxicity.
  • an antibody of the invention may be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or be modified to alter its glycosylation, again to alter one or more functional properties of the antibody.
  • the hinge region of CH1 is modified such that the number of cysteine residues in the hinge region is altered, e.g., increased or decreased.
  • This approach is described further in U.S. Pat. No. 5,677,425 by Bodmer et al.
  • the number of cysteine residues in the hinge region of CH1 is altered to, for example, facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody.
  • the Fc hinge region of an antibody is mutated to decrease the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment such that the antibody has impaired Staphylococcyl protein A (SpA) binding relative to native Fc-hinge domain SpA binding.
  • SpA Staphylococcyl protein A
  • the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector functions of the antibody.
  • one or more amino acids can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody.
  • the effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in, e.g., U.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.
  • one or more amino acids selected from amino acid residues can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or reduced or abolished complement dependent cytotoxicity (CDC).
  • CDC complement dependent cytotoxicity
  • one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is described in, e.g., the PCT Publication WO 94/29351 by Bodmer et al.
  • one or more amino acids of an antibody or antibody fragment thereof of the present invention are replaced by one or more allotypic amino acid residues, such as those shown in FIG. 4 for the IgG1 subclass and the kappa isotype.
  • Allotypic amino acid residues also include, but are not limited to, the constant region of the heavy chain of the IgG1, IgG2, and IgG3 subclasses as well as the constant region of the light chain of the kappa isotype as described by Jefferis et al., MAbs. 1:332-338 (2009).
  • the Fc region is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or to increase the affinity of the antibody for an Fc ⁇ receptor by modifying one or more amino acids.
  • ADCC antibody dependent cellular cytotoxicity
  • This approach is described in, e.g., the PCT Publication WO 00/42072 by Presta.
  • the binding sites on human IgG1 for Fc ⁇ R1, Fc ⁇ RII, Fc ⁇ RIII and FcRn have been mapped and variants with improved binding have been described (see Shields et al., J. Biol. Chem. 276:6591-6604, 2001).
  • the glycosylation of an antibody is modified.
  • an aglycosylated antibody can be made (i.e., the antibody lacks glycosylation).
  • Glycosylation can be altered to, for example, increase the affinity of the antibody for “antigen.”
  • Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence.
  • one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site.
  • Such aglycosylation may increase the affinity of the antibody for antigen.
  • Such an approach is described in, e.g., U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.
  • an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures.
  • altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies.
  • carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies of the invention to thereby produce an antibody with altered glycosylation.
  • glycoprotein-modifying glycosyl transferases e.g., beta(1,4)-N acetylglucosaminyltransferase III (GnTIII)
  • GnTIII glycoprotein-modifying glycosyl transferases
  • the antibody is modified to increase its biological half-life.
  • Various approaches are possible. For example, one or more of the following mutations can be introduced: T252L, T254S, or T256F, as described in U.S. Pat. No. 6,277,375 to Ward.
  • the antibody can be altered within the CH1 or C L region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, as described in U.S. Pat. Nos. 5,869,046 and 6,121,022 by Presta et al.
  • the present invention provides site-specific labeling methods, modified antibodies and antibody fragments thereof, and immunoconjugates prepared accordingly.
  • a modified antibody or antibody fragments thereof can be conjugated to a label, such as a drug moiety, e.g., an anti-cancer agent, an autoimmune treatment agent, an anti-inflammatory agent, an antifungal agent, an antibacterial agent, an anti-parasitic agent, an anti-viral agent, or an anesthetic agent, or an imaging reagent, such as a chelator for PET imaging, or a fluorescent label, or a MRI contrast reagent.
  • An antibody or antibody fragments can also be conjugated using several identical or different labeling moieties combining the methods of the invention with other conjugation methods.
  • the immunoconjugates of the present invention comprise a drug moiety selected from a V-ATPase inhibitor, a HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizer, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), an inhibitor of nuclear export of proteins CRM1, a DPPIV inhibitor, proteasome inhibitors, an inhibitor of phosphoryl transfer reactions in mitochondria, a protein synthesis inhibitor, a kinase inhibitor, a CDK2 inhibitor, a CDK9 inhibitor, an HDAC inhibitor, a DNA damaging agent, a DNA alkylating agent, a DNA intercalator, a DNA minor groove binder, topoisomerase inhibitors, RNA synthesis inhibitors, kinesin inhibitors, inhibitors of protein-protein interactions, and a DHFR inhibitor.
  • a drug moiety selected from a V-ATP
  • the modified antibodies or antibody fragments of the present invention may be conjugated to a drug moiety that modifies a given biological response.
  • Drug moieties are not to be construed as limited to classical chemical therapeutic agents.
  • the drug moiety may be an immune modulator, such as an immune potentiator, a small molecule immune potentiator, a TLR agonist, a CpG oligomer, a TLR2 agonist, a TLR4 agonist, a TLR7 agonist, a TLR9 agonist, a TLR8 agonist, a T-cell epitope peptide or a like.
  • the drug moiety may also be an oligonucleotide, a siRNA, a shRNA, a cDNA or a like.
  • the drug moiety may be a protein, peptide, or polypeptide possessing a desired biological activity.
  • Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin, a protein such as tumor necrosis factor, ⁇ -interferon, ⁇ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, a cytokine, an apoptotic agent, an anti-angiogenic agent, or, a biological response modifier such as, for example, a lymphokine.
  • a toxin such as abrin, ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin
  • a protein such as tumor necrosis factor, ⁇ -interferon, ⁇ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, a cytokine, an apoptotic agent, an anti-angiogenic agent, or, a biological response
  • the modified antibodies or antibody fragments of the present invention are conjugated to a drug moiety, such as a cytotoxin, a drug (e.g., an immunosuppressant) or a radiotoxin.
  • a drug moiety such as a cytotoxin, a drug (e.g., an immunosuppressant) or a radiotoxin.
  • cytotoxin include but not limited to, taxanes (see, e.g., International (PCT) Patent Application Nos.
  • DNA-alkylating agents e.g., CC-1065 analogs
  • anthracyclines e.g., tubulysin analogs
  • duocarmycin analogs e.g., auristatin E
  • auristatin F e.g., maytansinoids
  • cytotoxic agents comprising a reactive polyethylene glycol moiety (see, e.g., Sasse et al., J. Antibiot. (Tokyo), 53, 879-85 (2000), Suzawa et al., Bioorg. Med. Chem., 8, 2175-84 (2000), Ichimura et al., J. Antibiot.
  • WO 01/49698 taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, and puromycin and analogs or homologs thereof.
  • Therapeutic agents also include, for example, anti-metabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), ablating agents (e.g., mechlorethamine, thiotepa chlorambucil, meiphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin, anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g.,
  • An example of a calicheamicin antibody conjugate is commercially available (MylotargTM; Wyeth-Ayerst).
  • modified antibodies or antibody fragments thereof can also be conjugated to a radioactive isotope to generate cytotoxic radiopharmaceuticals, referred to as radioimmunoconjugates.
  • radioactive isotopes that can be conjugated to antibodies for use diagnostically or therapeutically include, but are not limited to, iodine 131 , indium 111 , yttrium 90 , and lutetium 177 . Methods for preparing radioimmunoconjugates are established in the art.
  • radioimmunoconjugates are commercially available, including ZevalinTM (DEC Pharmaceuticals) and BexxarTM (Corixa Pharmaceuticals), and similar methods can be used to prepare radioimmunoconjugates using the antibodies of the invention.
  • the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule.
  • linker molecules are commonly known in the art and described in Denardo et al., (1998) Clin. Cancer Res. 4(10):2483-90; Peterson et al., (1999) Bioconjug. Chem. 10(4):553-7; and Zimmerman et al., (1999) Nucl. Med. Biol. 26(8):943-50, each incorporated by reference in their entireties.
  • the present invention further provides modified antibodies or fragments thereof that specifically bind to an antigen.
  • the modified antibodies or fragments may be conjugated or fused to a heterologous protein or polypeptide (or fragment thereof, preferably to a polypeptide of at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids) to generate fusion proteins.
  • the invention provides fusion proteins comprising an antibody fragment described herein (e.g., a Fab fragment, Fd fragment, Fv fragment, F(ab)2 fragment, a V H domain, a V H CDR, a V L domain or a V L CDR) and a heterologous protein, polypeptide, or peptide.
  • modified antibody fragments without antigen binding specificity such as but not limited to, modified Fc domains with engineered cysteine residue(s) according to the present invention, are used to generate fusion proteins comprising such an antibody fragment (e.g., engineered Fc) and a heterologous protein, polypeptide, or peptide.
  • DNA shuffling may be employed to alter the activities of antibodies of the invention or fragments thereof (e.g., antibodies or fragments thereof with higher affinities and lower dissociation rates). See, generally, U.S. Pat. Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458; Patten et al., (1997) Curr. Opinion Biotechnol. 8:724-33; Harayama, (1998) Trends Biotechnol.
  • Antibodies or fragments thereof, or the encoded antibodies or fragments thereof may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination.
  • a polynucleotide encoding an antibody or fragment thereof that specifically binds to an antigen may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.
  • the modified antibodies or antibody fragments thereof of the present invention can be conjugated to marker sequences, such as a peptide to facilitate purification.
  • the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available.
  • hexa-histidine provides for convenient purification of the fusion protein.
  • peptide tags useful for purification include, but are not limited to, the hemagglutinin (“HA”) tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., (1984) Cell 37:767), and the “FLAG” tag (A. Einhauer et al., J. Biochem. Biophys. Methods 49: 455-465, 2001).
  • HA hemagglutinin
  • FLAG A. Einhauer et al., J. Biochem. Biophys. Methods 49: 455-465, 2001.
  • antibodies or antibody fragments can also be conjugated to tumor-penetrating peptides in order to enhance their efficacy.
  • modified antibodies or antibody fragments of the present invention are conjugated to a diagnostic or detectable agent.
  • immunoconjugates can be useful for monitoring or prognosing the onset, development, progression and/or severity of a disease or disorder as part of a clinical testing procedure, such as determining the efficacy of a particular therapy.
  • Such diagnosis and detection can accomplished by coupling the antibody to detectable substances including, but not limited to, various enzymes, such as, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic groups, such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials, such as, but not limited to, Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor 750, umbelliferone, fluorescein, fluorescein isothiocyan
  • Modified antibodies or antibody fragments of the invention may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen.
  • solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
  • compositions including immunoconjugates are mixed with a pharmaceutically acceptable carrier or excipient.
  • the compositions can additionally contain one or more other therapeutic agents that are suitable for treating or preventing cancer (breast cancer, colorectal cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, gastric cancer, pancreatic cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, peripheral nerve sheath tumors (e.g., schwannoma), head and neck cancer, bladder cancer, esophageal cancer, Barretts esophageal cancer, glioblastoma, clear cell sarcoma of soft tissue, malignant mesothelioma, neurofibromatosis, renal cancer, melanoma, prostate cancer, benign prostatic hyperplasia (BPH), gynacomastica, and endometriosis).
  • cancer breast cancer, colorectal cancer, lung cancer, multiple
  • Formulations of therapeutic and diagnostic agents can be prepared by mixing with physiologically acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions, lotions, or suspensions (see, e.g., Hardman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y., 2001; Gennaro, Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, N.Y., 2000; Avis, et al.
  • an administration regimen for a therapeutic depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells in the biological matrix.
  • an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects.
  • the amount of biologic delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate doses of antibodies, cytokines, and small molecules is available (see, e.g., Wawrzynczak, Antibody Therapy, Bios Scientific Pub.
  • Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects.
  • Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors known in the medical arts.
  • compositions comprising antibodies or fragments thereof of the invention can be provided by continuous infusion, or by doses at intervals of, e.g., one day, one week, or 1-7 times per week.
  • Doses may be provided intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscular, intracerebrally, or by inhalation.
  • a specific dose protocol is one involving the maximal dose or dose frequency that avoids significant undesirable side effects.
  • the dosage administered to a patient may be 0.0001 mg/kg to 100 mg/kg of the patient's body weight.
  • the dosage may be between 0.0001 mg/kg and 20 mg/kg, 0.0001 mg/kg and 10 mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg, 0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to 0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10 mg/kg, 0.001 to 0.5 mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's body weight.
  • the dosage of the antibodies or fragments thereof of the invention may be calculated using the patient's weight in kilograms (kg) multiplied by the dose to be administered in mg/kg.
  • Doses of the immunoconjugates the invention may be repeated and the administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months. In a specific embodiment, does of the immunoconjugates of the invention are repeated every 3 weeks.
  • An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side effects (see, e.g., Maynard et al., A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, Fla., 1996; Dent, Good Laboratory and Good Clinical Practice, Urch Publ., London, UK, 2001).
  • the route of administration may be by, e.g., topical or cutaneous application, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intracerebrospinal, intralesional, or by sustained release systems or an implant (see, e.g., Sidman et al., Biopolymers 22:547-556, 1983; Langer et al., J. Biomed. Mater. Res. 15:167-277, 1981; Langer, Chem. Tech. 12:98-105, 1982; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692, 1985; Hwang et al., Proc.
  • composition may also include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection.
  • pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos. WO 92/19244, WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903, each of which is incorporated herein by reference their entirety.
  • a composition of the present invention may also be administered via one or more routes of administration using one or more of a variety of methods known in the art.
  • routes of administration include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal or other parenteral routes of administration, for example by injection or infusion.
  • Parenteral administration may represent modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.
  • a composition of the invention can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.
  • the immunoconjugates of the invention is administered by infusion.
  • the immunoconjugates of the invention is administered subcutaneously.
  • a pump may be used to achieve controlled or sustained release (see Langer, supra; Sefton, CRC Crit. Ref Biomed. Eng. 14:20, 1987; Buchwald et al., Surgery 88:507, 1980; Saudek et al., N. Engl. J. Med. 321:574, 1989).
  • Polymeric materials can be used to achieve controlled or sustained release of the therapies of the invention (see e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla., 1974; Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York, 1984; Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61, 1983; see also Levy et al., Science 228:190, 1985; During et al., Ann. Neurol. 25:351, 1989; Howard et al., J. Neurosurg. 7 1:105, 1989; U.S. Pat. No.
  • polymers used in sustained release formulations include, but are not limited to, poly(-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters.
  • the polymer used in a sustained release formulation is inert, free of leachable impurities, stable on storage, sterile, and biodegradable.
  • a controlled or sustained release system can be placed in proximity of the prophylactic or therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138, 1984).
  • the immunoconjugates of the invention are administered topically, they can be formulated in the form of an ointment, cream, transdermal patch, lotion, gel, shampoo, spray, aerosol, solution, emulsion, or other form well-known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms, 19th ed., Mack Pub. Co., Easton, Pa. (1995).
  • viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity, in some instances, greater than water are typically employed.
  • Suitable formulations include, without limitation, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) for influencing various properties, such as, for example, osmotic pressure.
  • auxiliary agents e.g., preservatives, stabilizers, wetting agents, buffers, or salts
  • Other suitable topical dosage forms include sprayable aerosol preparations wherein the active ingredient, in some instances, in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as FreonTM) or in a squeeze bottle.
  • a pressurized volatile e.g., a gaseous propellant, such as FreonTM
  • compositions comprising the immunoconjugates are administered intranasally, it can be formulated in an aerosol form, spray, mist or in the form of drops.
  • prophylactic or therapeutic agents for use according to the present invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • a second therapeutic agent e.g., a cytokine, steroid, chemotherapeutic agent, antibiotic, or radiation
  • a second therapeutic agent e.g., a cytokine, steroid, chemotherapeutic agent, antibiotic, or radiation
  • An effective amount of therapeutic may decrease the symptoms by at least 10%; by at least 20%; at least about 30%; at least 40%, or at least 50%.
  • Additional therapies which can be administered in combination with the immunoconjugates of the invention may be administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours apart from the immunoconjugates of the invention.
  • the immunoconjugates of the invention can be formulated to ensure proper distribution in vivo.
  • the blood-brain barrier excludes many highly hydrophilic compounds.
  • the therapeutic compounds of the invention cross the BBB (if desired)
  • they can be formulated, for example, in liposomes.
  • liposomes For methods of manufacturing liposomes, see, e.g., U.S. Pat. Nos. 4,522,811; 5,374,548; and 5,399,331.
  • the liposomes may comprise one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, e.g., Ranade, (1989) J. Clin. Pharmacol. 29:685).
  • Exemplary targeting moieties include folate or biotin (see, e.g., U.S. Pat. No. 5,416,016 to Low et al.); mannosides (Umezawa et al., (1988) Biochem. Biophys. Res. Commun 153:1038); antibodies (Bloeman et al., (1995) FEBS Lett. 357:140; Owais et al., (1995) Antimicrob. Agents Chemother. 39:180); surfactant protein A receptor (Briscoe et al., (1995) Am. J. Physiol. 1233:134); p 120 (Schreier et al, (1994) J. Biol. Chem. 269:9090); see also K. Keinanen; M. L. Laukkanen (1994) FEBS Lett. 346:123; J. J. Killion; I. J. Fidler (1994) Immunomethods 4:273.
  • biotin
  • the invention provides protocols for the administration of pharmaceutical composition comprising immunoconjugates of the invention alone or in combination with other therapies to a subject in need thereof.
  • the therapies e.g., prophylactic or therapeutic agents
  • the therapy e.g., prophylactic or therapeutic agents
  • the combination therapies of the present invention can also be cyclically administered.
  • Cycling therapy involves the administration of a first therapy (e.g., a first prophylactic or therapeutic agent) for a period of time, followed by the administration of a second therapy (e.g., a second prophylactic or therapeutic agent) for a period of time and repeating this sequential administration, i.e., the cycle, in order to reduce the development of resistance to one of the therapies (e.g., agents) to avoid or reduce the side effects of one of the therapies (e.g., agents), and/or to improve, the efficacy of the therapies.
  • a first therapy e.g., a first prophylactic or therapeutic agent
  • a second therapy e.g., a second prophylactic or therapeutic agent
  • the therapies e.g., prophylactic or therapeutic agents
  • the combination therapies of the invention can be administered to a subject concurrently.
  • each therapy may be administered to a subject at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect.
  • Each therapy can be administered to a subject separately, in any appropriate form and by any suitable route.
  • the therapies are administered to a subject less than 15 minutes, less than 30 minutes, less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, 24 hours apart, 48 hours apart, 72 hours apart, or 1 week apart.
  • two or more therapies are administered to a within the same patient visit.
  • the prophylactic or therapeutic agents of the combination therapies can be administered to a subject in the same pharmaceutical composition.
  • the prophylactic or therapeutic agents of the combination therapies can be administered concurrently to a subject in separate pharmaceutical compositions.
  • the prophylactic or therapeutic agents may be administered to a subject by the same or different routes of administration.
  • 88 residues were selected for Cys substitution, 59 sites in hIgG heavy chain and 29 in human kappa light chain, based on the following criteria: 1) select residues in CH1, CH2 and CH3 domains of the constant regions of heavy chain and the constant regions of light chain; 2) select surface exposed residues but circumvent globally exposed residues and the C-terminal region to avoid inter-antibody dimer formation; 3) focus on polar or charged residues such as Ser, Thr, Lys, Arg, Glu, and Asp; and 4) exclude residues in FcRn binding domain, Protein A binding domain, and heavy chain hinge region.
  • Criterion 1) namely the selection of Cys substitution sites in the constant region of the antibody, assures transferability of the conjugation sites to many different antibodies.
  • Criterion 2) is based on observation of inter-antibody dimer formation for Cys substitutions of prominently exposed residues (residues excluded based on this criteria are listed in Table 6). Based on the IgG crystal structure, the putative orientation of the Cys side chain was taking into consideration: residues for which the Cys side chain may be partially shielded from interactions with another antibody but may still be reactive with a small molecular payload, were favored over residues with larger surface accessibility but with an orientation that may enable interactions with a large macromolecule such as dimer formation.
  • Criterion 3 was implemented to favor conservative mutations in order to minimize destabilizing effects of the mutations on the antibody.
  • criterion 4 was used to avoid functional changes to the antibody such as effects on FcRn and Protein A binding which may affect the antibody's pharmacokinetic properties or may result in the loss of a purification handle, respectively. Residues excluded based on criterion 4 are listed in Table 6. The location of the 88 selected mutation sites in the structure model of hIgG1/kappa indicates that the selected sites are surface accessible ( FIG. 2 ).
  • DNA encoding variable regions of heavy and light chains of trastuzumab were chemically synthesized and cloned into two mammalian expression vectors, pOG-HC and pOG-LC that contain constant regions of human IgG1 and human kappa light chain, resulting in two wild-type constructs, pOG-trastuzumab HC and pOG-trastuzumab LC, respectively.
  • pOG-HC and pOG-LC that contain constant regions of human IgG1 and human kappa light chain, resulting in two wild-type constructs, pOG-trastuzumab HC and pOG-trastuzumab LC, respectively.
  • the expression of antibody heavy and light chain constructs in mammalian cells is driven by a CMV promoter.
  • the vectors contain a synthetic 24 amino acid signal sequence: MKTFILLLWVLLLWVIFLLPGATA (SEQ ID NO: 99), in the N-terminal of heavy chain or light chain to guide their secretion from mammalian cells.
  • the signal sequence has been validated to be efficient in directing protein secretion in hundreds of mammalian proteins in 293 FreestyleTM cells.
  • Oligonucleotide directed mutagenesis was employed to prepare Cys mutant constructs in trastuzumab.
  • 88 pairs of mutation primers (Table 8) were chemically synthesized that correspond to the 88 Cys mutation sites selected in the constant regions of human IgG1 heavy chain and kappa light chain as described in Example 1.
  • PCR reactions were performed by using PfuUltra II Fusion HS DNA Polymerase (Stratagene) with pOG-trastuzumab HC and pOG-trastuzumab LC as the templates. After PCR reactions, the PCR products were confirmed on agarose gels, and treated with DPN I followed by transformation in DH5a cells (Klock et al., (2009) Methods Mol Biol. 498:91-103).
  • SEQ ID NO: 1 is the sequence for full-length trastuzumab (human IgG1).
  • SEQ ID NO: 2 to SEQ ID NO: 60 indicate the sequence ID numbers for 59 Cys mutant constructs in human IgG1 heavy chain, showing only the sequences of the constant region.
  • SEQ ID NO: 61 is the sequence of the constant region of wild-type human kappa light chain.
  • SEQ ID NO: 62 to SEQ ID NO: 90 indicate the sequence ID numbers for 29 Cys mutant constructs in the constant region of human kappa light chain.
  • the DNA encoding variable region of antibody 14090 was cloned into seven selected pOG trastuzumab HC Cys mutant plasmid constructs (SEQ ID NO listed in Table 11) to replace the variable regions of trastuzumab constructs in the plasmids as described in Example 2.
  • SEQ ID NO listed in Table 11 the amino acid sequences of the heavy chain constant regions in corresponding seven Cys constructs of antibody 14090 and trastuzumab are identical ( FIG. 3 ).
  • Subsequent examples show that these sites can be conjugated readily.
  • FIG. 3 due to a high degree of similarity in primary sequences and in tertiary structures for different human IgG isotypes.
  • Cys mutations on the kappa light chain of trastuzumab can readily be transferred to equivalent light chains on human antibodies containing different isotype heavy chains.
  • the sites identified in the constant region of IgG1 may be transferred to IgG2, IgG3 and IgG4.
  • FIG. 5A Human lambda and kappa light chains have little amino acid sequence similarity.
  • Mutations in the lambda light chain of antibody 14090 were selected based on the approximate similarity of the locations of the residues in a protein crystal structure model (Protein Databank structure entry 3G6D.pdb) of a Fab containing the human lambda light chain in reference to the desirable residues in the kappa light chain of trastuzumab ( FIGS. 5 A and B). Seven additional Cys mutant constructs were generated in antibody 14090-lambda light chain plasmid using oligonucleotide directed mutagenesis (Higuchi et al.
  • the mutation primers used to generate Cys point mutations in the lambda light chain are listed in Table 12.
  • the secretion of antibody 14090 is also directed by the synthetic 24 amino acid signal sequence: MKTFILLLWVLLLWVIFLLPGATA (SEQ ID NO: 99). Sequences of antibody 14090 Cys constructs were confirmed by DNA sequencing.
  • the sequence for the constant region of human wild-type lambda light chain is shown as SEQ ID NO:91.
  • the encoded protein sequences of seven Cys mutant constructs in the light chain (SEQ ID NO:92 to SEQ ID NO:98) are shown in Table 13. Subsequent examples will show that these Cys mutants are efficiently conjugated with an ADC payload. Because all of these mutants are in the constant region of the human lambda light chain, these conjugation sites can readily be transferred to other antibodies with lambda light chains.
  • SEQ ID NO: 91 is the sequence for the constant region of wild-type human lambda light chain.
  • SEQ ID NO: 91 to SEQ ID NO: 98 indicate the sequences of the 7 Cys mutants in the constant region of human lambda light chain of antibody 14090.
  • Cys mutants of the trastuzumab antibody were expressed in 293 FreestyleTM cells by co-transfecting heavy chain and light chain plasmids using transient transfection method as described previously (Meissner, et al., Biotechnol Bioeng. 75:197-203 (2001)).
  • the DNA plasmids used in co-transfection were prepared using Qiagen plasmid preparation kit according to manufacturer's protocol.
  • 293 FreestyleTM cells were cultured in suspension in FreestyleTM expression media (Invitrogen) at 37° C. under 5% CO 2 . On the day before transfection, cells were split to 0.7 ⁇ 10 6 cells/ml into fresh media. On the day of transfection, the cell density typically reached 1.5 ⁇ 10 6 cells/ml.
  • the cells were transfected with a mixture of heavy chain and light chain plasmids at the ratio of 1:1 using PEI method (Meissner et al., 2001). The transfected cells were further cultured for five days. The media from the culture was harvested by centrifugation of the culture at 2000 ⁇ g for 20 min and filtered through 0.2 micrometer filters. The expressed antibodies were purified from the filtered media using Protein A-SepharoseTM (GE Healthcare Life Sciences). Antibody IgGs were eluted from the Protein A-SepharoseTM column by the elution buffer (pH 3.0) and immediately neutralized with 1 M Tris-HCl (pH 8.0) followed by a buffer exchange to PBS.
  • the Cys mutants of antibody 14090 were also expressed in 293 FreestyleTM cells by co-transfecting HC and LC plasmids using PEI method as described (Meissner et al., 2001). The expression levels of the Cys mutants of antibody 14090 are similar to that of wild-type antibody 14090 (Table 16).
  • trastuzumab Cys mutant antibodies transiently expressed in 293 Freestyle TM cells. Yields were measured by UV absorbance at 280 nm after Protein A purification.
  • trastuzumab Purified trastuzumab Purified Cys mutant Ab (mg/L) Cys Mutant Ab (mg/L) HC-S117C 46.9 HC-R355C 30.1 HC-S119C 22.5 HC-K360C 32.0 HC-K121C 22.1 HC-Q362C 20.7 HC-S124C 17.8 HC-S375C 33.3 HC-S132C 30.9 HC-E382C 35.3 HC-S134C 18.6 HC-N389C 28.7 HC-S136C 21.2 HC-N390C 34.5 HC-T139C 25.9 HC-K392C 28.2 HC-E152C 13.0 HC-T393C 6.6 HC-P153C 10.8 HC-L3
  • engineered Cys in antibodies expressed in mammalian cells are modified by adducts (disulfides) such as glutathione (GSH) and/or Cysteine during their biosynthesis (Chen et al. 2009)
  • the modified Cys in the product as initially expressed is unreactive to thiol reactive reagents such as maleimido or bromo- or iodo-acetamide groups.
  • glutathione or cysteine adducts need to be removed by reducing these disulfides, which generally entails reducing all of the disulfides in the expressed protein.
  • DTT dithiothreitol
  • the antibodies are ready for conjugation.
  • Maleimide-MMAF (MC-MMAF, 10 equivalents relative to the antibody, FIG. 10 ) was added to re-oxidized antibodies in PBS buffer (pH7.2). The incubations were carried out from 1 hour to 24 hours.
  • the conjugation process was monitored by reverse-phase HPLC, which is able to separate conjugated antibodies from non-conjugated ones.
  • the conjugation reaction mixtures were analyzed on a PRLP-S 4000A column (50 mm ⁇ 2.1 mm, Agilent) heated to 80° C. and elution of the column was carried out by a linear gradient of 30-60% acetonitrile in water containing 0.1% TFA at a flow rate of 1.5 ml/min. The elution of proteins from the column was monitored at 280 nm, 254 nm and 215 nm.
  • the reverse-phase HPLC trace of a typical conjugation mixture is shown in FIG. 11 .
  • mismatched disulfide bonds may affect the retention of the antibody on the reverse-phase HPLC column.
  • the mismatch processes may also result in unpaired cysteine residues other than the desired engineered cysteine. Attachment of the maleimide-MMAF to different positions on the antibody affects the retention time differently (see discussion of homogenously conjugated ADCs below).
  • incomplete re-oxidation will leave the antibody with native cysteine residues that will react with maleimide-MMAF in addition to the desired conjugation with the engineered cysteine residue.
  • Cys-MMAF ADCs were analyzed in details in various assays: Differential scanning fluorimetry (DSF) was used to measure thermal stability. Analytical size exclusion chromatograph (AnSEC) was used to measure aggregation. In vitro antigen dependent cell killing potency was measured by cell viability assays and pharmacokinetics behavior was measured in mice. These assays and the respective results are described in more detail below.
  • the ADCs were analyzed in a size exclusion chromatography column (GE, Superdex200, 3.2/30) at a flow rate of 0.1 ml/min in PBS. All 65 Cys-MMAF ADCs were monomeric. The majority of the ADCs contain less than 10% oligomer ( FIG. 13 , Table 18), indicating that conjugation of MC-MMAF to trastuzumab Cys mutant constructs at the selected sites did not cause aggregation of the antibody.
  • trastuzumab Oligomer Conjugation Oligomer Cys-MMAF ADC site (%) HC-S117C b.d. HC-R344C 9.5 HC-S119C 3.2 HC-R355C b.d. HC-K121C b.d. HC-K360C b.d. HC-S124C b.d. HC-S375C b.d. HC-T139C 4.8 HC-E382C b.d. HC-E152C b.d.
  • Conjugation of MMAF payload to trastuzumab may stabilize or destabilize the antibody, leading to changes in melting temperature of the antibody, which can be determined by differential scanning fluorimetry (DSF) that is based on temperature induced denaturation monitored by an environmentally sensitive dye, such as sypro orange.
  • DSF differential scanning fluorimetry
  • ADC samples were aliquoted in triplicate to 384-well plates into PBS (6.7 mM sodium phosphate pH7.2; 150 mM NaCl). In each well, 8 ⁇ l of 0.25 mg/ml antibody was mixed with 2 ⁇ l 25 ⁇ sypro orange dye (Invitrogen). Plates were sealed and analyzed in a Roche LightCycler 480 system with a temperature ramp from 30 to 85° C. with 20 fluorescence scans recorded per degree C. Melting temperatures were determined from the first derivative of the fluorescence intensity vs. time curves.
  • a typical thermal shift assay for wild-type trastuzumab revealed two melting transitions (Tm), Tm1 at 69.7° C. and Tm2 at 81.2° C., respectively (Table 19).
  • trastuzumab Cys-MMAF ADCs Melting temperatures Tm1 and Tm2 of trastuzumab Cys-MMAF ADCs observed by differential scanning fluorimetry (DSF). trastuzumab Cys-MMAF ADC HC domain Tm1 [° C.] Tm2 [° C.] wild type antibody n.a.
  • MDA-MB231 clone 16 cells stably express high copy numbers ( ⁇ 5 ⁇ 10 5 copies/cell) of recombinant human Her2 while clone 40 expresses low copy numbers ( ⁇ 5 ⁇ 10 3 copies/cell) of human Her2.
  • HCC1954 cells endogenously express high level ( ⁇ 5 ⁇ 10 5 copies/cell) of human Her2 in the surface.
  • CMK11-5 and Jurkat cells were used for determination of the cell killing potency of antibody 14090 ADCs. While CMK11-5 cells express a high level of the antigen for antibody 14090 in the cell surface there is no detectable antigen expression in Jurkat cells. An antigen dependent cytotoxic effect should only kill cells that express sufficient antigen in the cell surface and not cells lacking the antigen.
  • the cell proliferation assays were conducted with Cell-Titer-GloTM (Promega) five days after cells were incubated with various concentrations of ADCs (Riss et al., (2004) Assay Drug Dev Technol. 2:51-62). In some studies, the cell based assays are high throughput and conducted in an automated system (Melnick et al., (2006) Proc Natl Acad Sci USA. 103:3153-3158).
  • Trastuzumab Cys-MMAF ADCs specifically killed MDA-MB231 clone 16 and HCC1954 but not MDA-MB231 clone 40 cells ( FIG. 15 ).
  • IC 50 of the trastuzumab Cys-MMAF ADCs in MDA-MB231 clone 16 cell assays ranges from 30 pM to 200 pM (Table 20, FIG. 16 ).
  • antibody 14090 Cys-MMAF ADC displayed antigen dependent cell killing in cell proliferation assays.
  • the antibody 14090 Cys-MMAF ADCs killed antigen expressing CMK11-5 cells but not antigen negative Jurkat cells ( FIG. 17 ).
  • the IC 50 of the antibody 14090-MMAF ADC in CMK11-5 proliferation assay is in the range of 400 pM to 1 nM (Table 21).
  • MMAF ADCs To evaluate the effects of different conjugation site on clearance of MMAF ADCs in vivo, pharmacokinetic studies in non-tumor bearing mice were carried out with 65 trastuzumab Cys-MMAF ADCs. To detect MMAF containing ADCs in murine plasma, an anti-MMAF antibody was generated. ELISA assays for the detection of ADCs were developed using the extracellular domain of human HER2 to capture trastuzumab IgG molecules from the plasma and an anti-human IgG (anti-hIgG) antibody and the anti-MMAF antibody for signal generation in two separate assays. The two ELISA assays measure the serum concentration of the trastuzumab antibody and the “intact” ADC respectively as discussed in more detail below.
  • mice per group were administered with a single dose of a trastuzumab Cys-MMAF ADC at 1 mg/kg.
  • Ten plasma samples were collected over the course of two weeks and assayed by ELISA using the extracellular domain of human HER2 to capture all trastuzumab IgG molecules including trastuzumab Cys-MMAF ADCs and trastuzumab lacking MMAF.
  • An anti-MMAF and an anti-hIgG antibody were then used for detection in two separate assays.
  • the anti-MMAF antibody ELISA measures the concentration of trastuzumab MMAF conjugates only and the anti-hIgG ELISA quantitates both trastuzumab Cys-MMAF conjugates and trastuzumab antibodies that lack MMAF. Standard curves were generated for each ADC separately using the same material as injected into the mice. The assays with anti-MMAF and anti-hIgG should therefore yield identical concentration readouts if no changes to the drug loading of the trastuzumab Cys-MMAF ADC occur after injection into mice.
  • the ELISA assay with the anti-MMAF antibody will measure a lower concentration than the anti-hIgG ELISA. A comparison of the two concentration readouts therefore allows to measure drug-release from trastuzumab Cys-MMAF ADCs during in vivo incubation in the mouse.
  • 63 out of 65 ADCs displayed a pharmacokinetic profile similar to unconjugated wild-type trastuzumab antibody ( FIGS. 18 , 19 , 20 ), indicating that MC-MMAF payload conjugation to these sites did not significantly affect the antibody's clearance.
  • the two exceptions are HC-T335C and HC-S337C. Conjugation of MC-MMAF to these two sites results in rapid clearance of the ADCs as measured by the anti-MMAF and the anti-hIgG ELISA ( FIG. 21 ).
  • the protein thermal shift assay revealed that the Tm1 for trastuzumab HC-T335C-MMAF and trastuzumab HC-S337C-MMAF decreased from 69° C. in wild-type trastuzumab antibody to 42° C. and 45° C., respectively ( FIG. 14 ).
  • Conjugation of MC-MMAF to the two sites dramatically reduces the thermal stability of the ADC (by 27° C. and 24° C., respectively).
  • Tm1 changes were smaller than 8° C. suggesting that fast clearance may possibly correlate with low thermal stability of the ADC.
  • trastuzumab Cys-MMAF ADCs displayed a significant drug loss as indicated by the higher anti-hIgG readout than the anti-MMAF readout ( FIG. 20 ).
  • concentration of ADC was about 50% of that of hIgG.
  • AUC area-under-the-plasma-concentration-versus-time-curve
  • Sites in Table 22 having an AUC(MMAF)/AUC(hIgG) ratio greater than 0.7 are therefore particularly suitable sites for cysteine substitution based on this criterion, and sites having a ratio of about 0.9 or above are especially preferred cysteine substitution sites for purposes of the invention when applying.
  • These include heavy chain sites 322, 334, 121, 288, 171, 139, 360, 117, 392, 375, 292, 333, 174, 258, 337, 422, 320, 390, and 335; and light chain sites 107, 203, 108 and 114.
  • Antibody conjugates produced through conjugation to lysine residues or partially reduced native disulfide bonds often feature drug-to-antibody-ratios (DAR) of between 3 and 4. Cys engineered antibodies more typically feature a DAR of 2. For certain indications, it may be desirable to produce ADCs with higher DAR which can in principle be achieved by introducing multiple Cys mutations in the antibody. As the number of Cys mutation increases, the likelihood that such mutations interfere with the required re-oxidation process during ADC preparation and hence result in heterogeneous products also increases. In this study, a large number of single site heavy and light chain Cys mutants with good re-oxidation behavior were identified.
  • DAR drug-to-antibody-ratios
  • the DAR of all ADCs in Table 23 was confirmed to be 4 by mass spectrometry. Production yields varied from 16 to 24 mg/L transient cell culture.
  • the ADCs were predominantly monomeric as determined by analytical size exclusion chromatography; only for 2 of the 8 antibodies could small amounts of aggregates be detected (Table 23).
  • Trastuzumab and 14090 ADCs exhibited antigen-dependent cell killing in MDA-MB231 clone 16 and CMK1105 cell proliferation assays, respectively (Table 23).
  • the surprisingly large differences in retention times can be rationalized from the inspection of location of the attachment sites on the structure of an antibody ( FIG. 24 ):
  • the retention times are higher if the drug payload is attached at an exposed site on the outside of an antibody, for example at HC-K288Pcl, HC-N286Pcl, HC-V422Pcl, HC-L398Pcl and HC-S415Pcl where retention time between 87 and 94 mM were measured for the respective ADCs ( FIG. 23 ).
  • the payload is attached at an interior site such as the cavity formed between variable and CH1 domains (for examples, HC-P153Pcl, HC-E152Pcl, HC-L174Pcl, HC-P171Pcl, LC-R142Pcl, LC-E161Pcl, LC-E165Pcl, LC-S159Pcl) or the large opening between CH2 and CH3 domains of the antibody (for examples, HC-K246C, HC-S375Pcl, HC-T393Pcl, HC-K334Pcl), the HIC retention time increased to only 47 to 57 mins because the payload is partially sequestered from interacting with solvent and the HIC column. For other sites, for example, the relatively exposed sites, LC-K107Pcl and HC-K360Pcl, intermediate retention time of 70 and 83 min were measured.
  • variable and CH1 domains for examples, HC-P153Pcl, HC-
  • Reducing hydrophobicity of a protein drug is generally considered beneficial because it may reduce aggregation and clearance from circulation.
  • HIC data presented in FIG. 23 enables selection of preferred payload attachment sites. Conjugating drug payloads at sites where they are sequestered from solvent interactions and attachment minimally increases the hydrophobicity of the antibody upon drug attachment should be beneficial independent of the conjugation chemistry and payload class. Carefully selecting attachment sites that result in minimal changes in hydrophobicity may be particularly beneficial when 4, 6 or 8 drugs are attached per antibody, or when particularly hydrophobic payloads are used.
  • HC-E333C, HC-K392C, and HC-K326C results in MMAF ADCs that have HIC retention times that are similar to the exposed site ADCs LC-K107C-MMAF, HC-E258C-MMAF, HC-R292C-MMAF and HC-K360C-MMAF (Table 28).
  • Attachment to the HC-E152C, LC-E165C, HC-P171C, LC-R142C, LC-E161C, HC-L174C and HC-S124C sites increases the retention time of the resulting ADC by less than 15% compared to the unconjugated, wild-type antibody.
  • CH3 domain sites HC-K334C and HC-S375C exhibit to lowest increase in hydrophobicity upon conjugation making them preferred attachment sites.
  • Cys mutant sites Cys mutant site Site (EU No.) LC-R142C 142 LC-S159C 159 LC-E161C 161 LC-E165C 165 HC-S124C 124 HC-E152C 152 HC-P171C 171 HC-L174C 174 HC-K326C 326 HC-E333C 333 HC-K334C 334 HC-S375C 375 HC-K392C 392
  • Cys mutations can be combined for the preparation of DAR 4, 6 and 8 ADCs.
  • the preferred combination is a combination of two Cys mutations resulting in ADCs with DAR 4.
  • HC heavy chain
  • LC light chain
  • Example 10 for trastuzumab and for antibody 14090. Additional data is provided in Table 26. Based on the HIC data and the inspection of attachment sites in the IgG crystal structures, additional Cys combinations were prepared using the protocols described in Examples 2, 5 and 6. Data for selected examples of MMAF ADCs are shown in Table 26.
  • selected heavy chain sites were combined and double Cys mutations of the heavy chain were cloned following protocols listed in Example 2.
  • Antibodies featuring two HC Cys mutations were prepared and conjugated following protocols described in Example 5 and 6.
  • combinations include single site mutations listed in Table 24. Combinations of single sites resulted in ADCs with low hydrophobicity (Table 25). In the some combination, one Cys mutation is located in the CH1 domain or on the light chain and the second site is located in the CH3 domain. Examples of such combinations are antibodies featuring Cys mutant combinations of HC-E152C and HC-S375C, and LC-E165C and HC-S375C, and HC-E152C and HC-K334C, and LC-E165C and HC-K334C.
  • ADCs with DAR 6 and 8 can also be prepared when three or four Cys mutations are combined in one antibody. Selected heavy chain combinations were combined for the preparations of DAR 4, 6 and 8 ADCs. Double and triple Cys mutations of the heavy chain were cloned following protocols listed in Example 2. Antibodies featuring two, three and four Cys mutations were prepared and conjugated following protocols described in Example 5 and 6. The characteristics of some DAR 4, DAR 6 and DAR 8 ADC examples are summarized in Table 26. Some of these ADCs have surprisingly good PK properties as shown in FIG. 25 . Antibody 14090 is mouse cross-reactive and therefore, antibody 14090 ADCs, as expected, are cleared more rapidly than trastuzumab ADCs which do not bind to any mouse antigens.
  • Combinations include those with three and four of the single site mutations listed in Table 24. Combinations include those sites that resulted in ADCs with low hydrophobicity (Table 25). Combinations include one Cys mutation is located in the CH1 domain or on the light chain (LC), and optionally an additional one to three sites are in the CH3 domain. Examples of such combinations include antibodies featuring Cys mutant combinations of HC-E152C or LC-E165C, with HC-S375C, with HC-K334C, and/or HC-K392C. Preferred combinations for the preparation of DAR 6 and DAR 8 ADCs are shown in Table 27 and Table 28 respectively.
  • ADC combination Site 1 Site 2 Site 3 1 HC-E152C HC-S375C HC-K392C 2 HC-E152C HC-S375C HC-K334C 3 HC-E152C HC-K334C HC-K392C 4 LC-E165C HC-S375C HC-K392C 5 LC-E165C HC-S375C HC-K334C 6 LC-E165C HC-K334C HC-K392C
  • ADC combination Site 1 Site 2 Site 3 Site 4 1 HC-E152C HC-S375C HC-K334C HC-K392C 2 HC-E152C HC-S375C HC-E333C HC-K392C 3 LC-E165C HC-S375C HC-K334C HC-K392C 4 LC-E165C HC-S375C HC-E333C HC-K392C
  • In vivo xenograft tumor models simulate biological activity observed iby grafting relevant and well characterized human primary tumors or tumor cell lines into immune-deficient nude mice.
  • Studies on treatment of tumor xenograft mice with anti-cancer reagents have provided valuable information regarding in vivo efficacy of the tested reagents (Sausville and Burger, 2006).
  • MDA-MB231 clone 16 cells were sensitive to trastuzumab Cys-MMAF ADCs in antigen dependent manner ( FIG. 15 ), the cell line was chosen as the in vivo model to evaluate the trastuzumab Cys-MMAF ADCs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US14/764,026 2013-02-08 2014-02-07 Specific sites for modifying antibodies to make immunoconjugates Abandoned US20160067351A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/764,026 US20160067351A1 (en) 2013-02-08 2014-02-07 Specific sites for modifying antibodies to make immunoconjugates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762563P 2013-02-08 2013-02-08
US14/764,026 US20160067351A1 (en) 2013-02-08 2014-02-07 Specific sites for modifying antibodies to make immunoconjugates
PCT/US2014/015393 WO2014124316A2 (fr) 2013-02-08 2014-02-07 Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/015393 A-371-Of-International WO2014124316A2 (fr) 2013-02-08 2014-02-07 Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/701,576 Continuation US11596695B2 (en) 2013-02-08 2019-12-03 Specific sites for modifying antibodies to make immunoconjugates

Publications (1)

Publication Number Publication Date
US20160067351A1 true US20160067351A1 (en) 2016-03-10

Family

ID=50179939

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/764,026 Abandoned US20160067351A1 (en) 2013-02-08 2014-02-07 Specific sites for modifying antibodies to make immunoconjugates
US16/701,576 Active 2035-02-11 US11596695B2 (en) 2013-02-08 2019-12-03 Specific sites for modifying antibodies to make immunoconjugates
US18/178,886 Pending US20230270876A1 (en) 2013-02-08 2023-03-06 Specific sites for modifying antibodies to make immunoconjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/701,576 Active 2035-02-11 US11596695B2 (en) 2013-02-08 2019-12-03 Specific sites for modifying antibodies to make immunoconjugates
US18/178,886 Pending US20230270876A1 (en) 2013-02-08 2023-03-06 Specific sites for modifying antibodies to make immunoconjugates

Country Status (20)

Country Link
US (3) US20160067351A1 (fr)
EP (2) EP3929217A3 (fr)
JP (1) JP6609477B2 (fr)
KR (3) KR102626525B1 (fr)
CN (2) CN115925957A (fr)
AU (2) AU2014214751B2 (fr)
BR (1) BR112015018899B1 (fr)
CA (1) CA2900755C (fr)
DK (1) DK2953976T3 (fr)
EA (1) EA201591465A1 (fr)
ES (1) ES2874493T3 (fr)
HK (1) HK1213580A1 (fr)
HU (1) HUE054443T2 (fr)
IL (1) IL240406B (fr)
MX (2) MX2015010146A (fr)
PL (1) PL2953976T3 (fr)
PT (1) PT2953976T (fr)
SG (2) SG11201506025RA (fr)
SI (1) SI2953976T1 (fr)
WO (1) WO2014124316A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015827A1 (en) * 2014-06-20 2016-01-21 Bioalliance C.V. Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof
US20160015831A1 (en) * 2014-06-20 2016-01-21 Bioalliance C.V. Anti-cd22 antibody-drug conjugates and methods of using thereof
WO2017112624A1 (fr) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Anticorps variants pour conjugaison spécifique à un site
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
KR20190065374A (ko) * 2016-10-08 2019-06-11 쓰촨 바이리 팜 컴퍼니, 리미티드 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
US10675358B2 (en) 2016-07-07 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US20210292391A1 (en) * 2020-02-28 2021-09-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
US20220175947A1 (en) * 2017-02-28 2022-06-09 Seagen Inc. Cysteine mutated antibodies for conjugation
US11364303B2 (en) * 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2022152289A1 (fr) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps modifié et conjugués anticorps-médicament le comprenant
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2023076599A1 (fr) * 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Immunoconjugués agonistes de tlr avec des anticorps mutants de cystéine, et leurs utilisations

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
JP2017500028A (ja) 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｄｐｅｐ３抗体および使用方法
PT3082877T (pt) 2013-12-17 2019-12-03 Novartis Ag Péptidos citotóxicos e seus conjugados
EP3107576A4 (fr) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anticorps anti-dll3 et conjugués de médicaments destinés à être utilisés dans un mélanome
WO2015138615A2 (fr) * 2014-03-12 2015-09-17 Irm Llc Sites spécifiques utilisables pour la modification d'anticorps en vue de l'obtention d'immunoconjugués
AU2015243380B2 (en) 2014-04-11 2020-05-14 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
LT3151865T (lt) 2014-05-22 2021-10-25 Byondis B.V. Prijungiamų vaistų vietai specifinis konjugavimas su antikūnais ir to pasekoje gaunami avk
TW201625315A (zh) * 2014-06-20 2016-07-16 台醫國際股份有限公司 Ｈｅｒ２抗體－藥物共軛物
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
AR101844A1 (es) * 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
JP6862343B2 (ja) * 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
TWI778491B (zh) * 2015-11-30 2022-09-21 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
TWI812873B (zh) * 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
CA3038427A1 (fr) 2016-10-11 2018-04-19 Synthon Biopharmaceuticals B.V. Lieurs auto-immolables non lineaires et conjugues de ceux-ci
MX2019004434A (es) 2016-10-17 2019-09-26 Pfizer Anticuerpos anti-edb y conjugados anticuerpo-fármaco.
US11865135B2 (en) * 2016-12-07 2024-01-09 Innate Biotherapeutics, Llc ß-1,6-glucan therapeutic antibody conjugates
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
RU2765098C2 (ru) * 2017-02-28 2022-01-25 Иммуноджен, Инк. Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
JP7073487B2 (ja) * 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
US20210393794A1 (en) * 2017-06-20 2021-12-23 Sichuan Baili Pharm Co.Ltd Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
JP7117088B2 (ja) * 2017-08-04 2022-08-12 シスメックス株式会社 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111683963B (zh) * 2017-10-03 2024-03-29 默克专利有限公司 半胱氨酸工程化的抗原结合分子
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
UY38265A (es) 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
WO2020089815A1 (fr) 2018-10-31 2020-05-07 Novartis Ag Conjugués d'anticorps comprenant un agoniste de sting
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
JOP20210159A1 (ar) 2018-12-21 2023-01-30 Novartis Ag أجسام مضادة لـ pmel17 ومترافقات منها
CN111675762B (zh) * 2019-03-11 2023-12-01 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體－藥物結合物及使用方法
KR20220010527A (ko) 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
US20230165967A1 (en) 2019-10-04 2023-06-01 TAE Life Sciences Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for use in Treating Cancer, Immunological Disorders, and Methods Thereof
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CA3198996A1 (fr) 2020-11-24 2022-06-02 Matthew T. Burger Conjugues anticorps-medicament inhibiteurs de bcl-xl et leurs procedes d'utilisation
EP4251648A2 (fr) 2020-11-24 2023-10-04 Novartis AG Anticorps anti-cd48, conjugués anticorps-médicament et leurs utilisations
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
AU2022222386A1 (en) 2021-02-16 2023-07-20 Glykos Finland Oy Linker-payloads and conjugates thereof
CA3235132A1 (fr) 2021-04-16 2022-10-20 Novartis Ag Conjugues anticorps-medicament et leurs procedes de fabrication
WO2023225336A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
WO2023225359A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament de composés anti-cancéreux et procédés d'utilisation
WO2023225320A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
WO2024099368A1 (fr) * 2022-11-08 2024-05-16 Westlake University Marqueurs peptidiques, compositions et procédés de conjugaison de protéines spécifiques à un site
WO2024129756A1 (fr) 2022-12-13 2024-06-20 Seagen Inc. Conjugués anticorps-médicament modifiés par la cystéine spécifiques d'un site
WO2024189481A1 (fr) 2023-03-10 2024-09-19 Novartis Ag Conjugués anticorps-médicament inhibiteurs de panras et leurs procédés d'utilisation

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060039904A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. EPH receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006034488A2 (fr) * 2004-09-23 2006-03-30 Genentech, Inc. Anticorps et conjugués produits avec de la cystéine
US20080050310A1 (en) * 2006-05-30 2008-02-28 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20080311134A1 (en) * 2007-05-08 2008-12-18 Junutula Jagath R Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US20100158909A1 (en) * 2006-12-01 2010-06-24 Seattle Genetics, Inc. Variant Target Binding Agents and Uses Thereof
US20110033378A1 (en) * 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
US20110135667A1 (en) * 2007-07-16 2011-06-09 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
US20110301334A1 (en) * 2010-06-08 2011-12-08 Sunil Bhakta Cysteine engineered antibodies and conjugates
US20120121615A1 (en) * 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US20120213705A1 (en) * 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US20130017200A1 (en) * 2009-12-04 2013-01-17 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20130066054A1 (en) * 2009-11-17 2013-03-14 Ucb Pharma S.A. Multivalent antibodies
US20130330350A1 (en) * 2010-11-09 2013-12-12 Medimmune, Llc Antibody Scaffold For Homogenous Conjugation
US20160008485A1 (en) * 2011-12-23 2016-01-14 Pfizer Inc. Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor
US9884817B2 (en) * 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
US9938323B2 (en) * 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
US9988420B2 (en) * 2013-12-17 2018-06-05 Novartis Ag Cytotoxic peptides and conjugates thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2429008A (en) 1945-12-01 1947-10-14 Diamond Chain & Mfg Company Sprocket or gear
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1991005548A1 (fr) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Composition a liberation entretenue pour proteines macromoleculaires
EP0550436A1 (fr) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Microspheres de proteines et leurs procedes d'utilisation
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
EP0640094A1 (fr) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
DE4444135B4 (de) 1994-12-11 2005-06-02 Gerold Tebbe Sauerstoff-Behandlungseinrichtung
EP0805678B1 (fr) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2230494A1 (fr) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition se pretant a la liberation prolongee d'un agent
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998031346A1 (fr) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP0985039B1 (fr) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Polypeptides d'anticorps artificiels
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
WO2001038318A1 (fr) 1999-11-24 2001-05-31 Immunogen, Inc. Agents cytotoxiques comprenant des taxanes et leur utilisation therapeutique
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2392923B1 (fr) 2003-06-18 2014-05-21 The Scripps Research Institute Méthode pour la production de protéines avec des acides aminés non naturels
US20050152894A1 (en) 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
US20060183888A1 (en) 2004-08-13 2006-08-17 Chan Michael K Pyrrolysine synthesis and modification
US20060166319A1 (en) 2004-08-13 2006-07-27 Chan Michael K Charging tRNA with pyrrolysine
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580796C (fr) 2004-09-24 2013-03-26 Amgen Inc. Molecules fc modifiees ayant des peptides inserees dans les regions de boucle interne
CA2587766A1 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
WO2008020827A2 (fr) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Polypeptides modifiés, immunoconjugués de ceux-ci et procédés apparentés
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
PL2845866T3 (pl) 2006-10-27 2017-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
US20100184959A1 (en) 2007-03-19 2010-07-22 Medimmune Limited Polypeptide Variants
WO2009034486A2 (fr) * 2007-09-10 2009-03-19 Nxp B.V. Procédé et appareil d'estimation de mouvement par rapport à des lignes dans des données d'images vidéo
US8937161B2 (en) 2007-10-19 2015-01-20 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
US8900589B2 (en) * 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
AU2009308163B2 (en) 2008-10-24 2013-01-10 Novartis Ag Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
CN102369218B (zh) * 2009-04-01 2014-07-16 霍夫曼-拉罗奇有限公司 抗-FcRH5抗体和免疫缀合物以及应用方法
CN101709047A (zh) 2009-05-25 2010-05-19 华东理工大学 第二十二种天然氨基酸-吡咯赖氨酸的化学全合成方法
KR20180056805A (ko) * 2009-06-04 2018-05-29 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
JP2012532838A (ja) 2009-07-09 2012-12-20 エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 安定化された免疫グロブリン定常ドメイン
GB0920324D0 (en) * 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2794905B1 (fr) * 2011-12-20 2020-04-01 MedImmune, LLC Polypeptides modifiés pour des échafaudages d'anticorps bispécifiques
WO2013125861A1 (fr) 2012-02-20 2013-08-29 주식회사 노리코리아 Procédé et système de fourniture d'un service éducatif sur la base d'une unité de connaissances, et support d'enregistrement lisible par ordinateur
EP2855520B1 (fr) 2012-06-04 2018-09-26 Novartis AG Méthodes de marquage spécifiques à un site et molécules ainsi produites
AU2013270684B2 (en) * 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014124258A2 (fr) 2013-02-08 2014-08-14 Irm Llc Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
WO2014151030A1 (fr) 2013-03-15 2014-09-25 Novartis Ag Inhibiteurs de la prolifération cellulaire et leurs conjugués
WO2015138615A2 (fr) 2014-03-12 2015-09-17 Irm Llc Sites spécifiques utilisables pour la modification d'anticorps en vue de l'obtention d'immunoconjugués
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US11605302B2 (en) 2020-11-10 2023-03-14 Rockwell Collins, Inc. Time-critical obstacle avoidance path planning in uncertain environments

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060039904A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. EPH receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006034488A2 (fr) * 2004-09-23 2006-03-30 Genentech, Inc. Anticorps et conjugués produits avec de la cystéine
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US7855275B2 (en) * 2004-09-23 2010-12-21 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20080050310A1 (en) * 2006-05-30 2008-02-28 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20100158909A1 (en) * 2006-12-01 2010-06-24 Seattle Genetics, Inc. Variant Target Binding Agents and Uses Thereof
US20080311134A1 (en) * 2007-05-08 2008-12-18 Junutula Jagath R Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US20110135667A1 (en) * 2007-07-16 2011-06-09 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
US20110033378A1 (en) * 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
US20120213705A1 (en) * 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US20130066054A1 (en) * 2009-11-17 2013-03-14 Ucb Pharma S.A. Multivalent antibodies
US20130017200A1 (en) * 2009-12-04 2013-01-17 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US20110301334A1 (en) * 2010-06-08 2011-12-08 Sunil Bhakta Cysteine engineered antibodies and conjugates
US20130330350A1 (en) * 2010-11-09 2013-12-12 Medimmune, Llc Antibody Scaffold For Homogenous Conjugation
US20120121615A1 (en) * 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US20160008485A1 (en) * 2011-12-23 2016-01-14 Pfizer Inc. Engineered Antibody Constant Regions for Site-Specific Conjugation and Methods and Uses Therefor
US9988420B2 (en) * 2013-12-17 2018-06-05 Novartis Ag Cytotoxic peptides and conjugates thereof
US9884817B2 (en) * 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
US9938323B2 (en) * 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Lund et al., The Journal of Immunology 157:4963-4969, 1996. *
Rudikoff et al., PNAS 79: 1979-1983 (Year: 1982) *
Strop et al., Chemistry & Biology 20: 161-167, 2013. *
Teicher et al., Clin Cancer Res 17(20): 6389-97, 2011. *
Wu et al., J Mol Biol 294: 151-162 (Year: 1999) *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US20160015831A1 (en) * 2014-06-20 2016-01-21 Bioalliance C.V. Anti-cd22 antibody-drug conjugates and methods of using thereof
US9950077B2 (en) * 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US20160015827A1 (en) * 2014-06-20 2016-01-21 Bioalliance C.V. Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof
WO2017112624A1 (fr) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Anticorps variants pour conjugaison spécifique à un site
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
US11110178B2 (en) 2016-07-07 2021-09-07 The Board Of Trustees Of The Leland Standford Junior University Antibody adjuvant conjugates
US10675358B2 (en) 2016-07-07 2020-06-09 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
EP3524273A4 (fr) * 2016-10-08 2020-07-15 Sichuan Baili Pharm Co., Ltd. Conjugué médicament-anticorps modifié par cystéine et son procédé de préparation
RU2762594C2 (ru) * 2016-10-08 2021-12-21 Сычуань Байли Фарм Ко., Лтд. Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения
KR102579211B1 (ko) * 2016-10-08 2023-09-15 쓰촨 바이리 파마슈티칼 컴퍼니, 리미티드 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법
KR20190065374A (ko) * 2016-10-08 2019-06-11 쓰촨 바이리 팜 컴퍼니, 리미티드 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법
KR102480873B1 (ko) * 2016-10-08 2022-12-26 쓰촨 바이리 파마슈티칼 컴퍼니, 리미티드 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법
KR20230003663A (ko) * 2016-10-08 2023-01-06 쓰촨 바이리 파마슈티칼 컴퍼니, 리미티드 시스테인 개조된 항체-약물 접합체(Cysteine modified antibody-drug conjugate) 및 그의 제조 방법
US11938194B2 (en) * 2017-02-28 2024-03-26 Seagen Inc. Cysteine mutated antibodies for conjugation
US20220175947A1 (en) * 2017-02-28 2022-06-09 Seagen Inc. Cysteine mutated antibodies for conjugation
US11364303B2 (en) * 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US11879004B2 (en) * 2020-02-28 2024-01-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
US20210292391A1 (en) * 2020-02-28 2021-09-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
WO2022152289A1 (fr) * 2021-01-18 2022-07-21 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps modifié et conjugués anticorps-médicament le comprenant
WO2023076599A1 (fr) * 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Immunoconjugués agonistes de tlr avec des anticorps mutants de cystéine, et leurs utilisations

Also Published As

Publication number Publication date
CA2900755A1 (fr) 2014-08-14
SG10201706468RA (en) 2017-09-28
MX2022010324A (es) 2022-09-19
IL240406B (en) 2020-02-27
AU2017219059A1 (en) 2017-09-14
WO2014124316A2 (fr) 2014-08-14
HUE054443T2 (hu) 2021-09-28
JP6609477B2 (ja) 2019-11-20
EP3929217A3 (fr) 2022-03-02
CN115925957A (zh) 2023-04-07
CA2900755C (fr) 2021-07-20
HK1213580A1 (zh) 2016-07-08
DK2953976T3 (da) 2021-06-21
ES2874493T3 (es) 2021-11-05
KR102626525B1 (ko) 2024-01-19
SI2953976T1 (sl) 2021-08-31
MX2015010146A (es) 2016-05-31
KR102447350B1 (ko) 2022-09-23
BR112015018899B1 (pt) 2023-09-26
EA201591465A1 (ru) 2015-12-30
AU2014214751A1 (en) 2015-08-20
AU2014214751B2 (en) 2017-06-01
US11596695B2 (en) 2023-03-07
EP2953976B1 (fr) 2021-03-24
US20230270876A1 (en) 2023-08-31
PT2953976T (pt) 2021-06-23
BR112015018899A2 (fr) 2015-08-06
PL2953976T3 (pl) 2021-11-02
KR20210125593A (ko) 2021-10-18
IL240406A0 (en) 2015-09-24
KR20220133313A (ko) 2022-10-04
JP2016511637A (ja) 2016-04-21
US20200338207A1 (en) 2020-10-29
SG11201506025RA (en) 2015-08-28
EP2953976A2 (fr) 2015-12-16
CN105143271A (zh) 2015-12-09
KR20150115000A (ko) 2015-10-13
WO2014124316A3 (fr) 2014-11-27
EP3929217A2 (fr) 2021-12-29

Similar Documents

Publication Publication Date Title
US11596695B2 (en) Specific sites for modifying antibodies to make immunoconjugates
US20170021033A1 (en) Specific sites for modifying antibodies to make immunoconjugates
EP2855520B1 (fr) Méthodes de marquage spécifiques à un site et molécules ainsi produites
WO2014124258A2 (fr) Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
EP3268038B1 (fr) Conjugués anticorps-médicament (cam) se liant aux protéines flt3
JP2018140997A (ja) 抗体−薬剤コンジュゲート
US20120078028A1 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
ES2930255T3 (es) Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
US11779649B2 (en) Antibodies to PMEL17 and conjugates thereof
JP2024056808A (ja) 胆道癌の治療のための、ｈｅｒ２を標的とする二重特異性抗原結合構築物の使用方法
EA043810B1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
KR20240040786A (ko) 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
TW202434312A (zh) 抗-ror2抗體、抗體片段、其免疫結合物及其用途

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BERMUD

Free format text: MERGER;ASSIGNOR:IRM LLC;REEL/FRAME:035444/0397

Effective date: 20150105

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.;REEL/FRAME:035453/0224

Effective date: 20150330

AS Assignment

Owner name: IRM LLC, BERMUDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF);REEL/FRAME:038636/0500

Effective date: 20140303

Owner name: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GEIERSTANGER, BERNHARD HUBERT;OU, WEIJIA;UNO, TETSUO;SIGNING DATES FROM 20140205 TO 20140220;REEL/FRAME:038635/0905

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION